
==== Front
Biomark Res
Biomark Res
Biomarker Research
2050-7771
BioMed Central London

39289775
652
10.1186/s40364-024-00652-3
Review
METTL protein family: focusing on the occurrence, progression and treatment of cancer
Zhang Huhu 1
Sun Fulin 12
Jiang Shuyao 12
Yang Fanghao 1
Dong Xiaolei 1
Liu Guoxiang 3
Wang Mengjun 1
Li Ya 1
Su Mohan 1
Wen Ziyuan 1
Yu Chunjuan 1
Fan Chenkai 12
Li Xiaoxia 1
Zhang Zhe 1
Yang Lina yanglina@qdu.edu.cn

1
Li Bing libing_516@qdu.edu.cn

14
1 https://ror.org/021cj6z65 grid.410645.2 0000 0001 0455 0905 Department of Genetics and Cell Biology, School of Basic Medicine, Qingdao University, Qingdao, 266071 China
2 grid.410645.2 0000 0001 0455 0905 Health Science Center, Qingdao University, Qingdao, 266071 China
3 https://ror.org/01xd2tj29 grid.416966.a 0000 0004 1758 1470 Department of Clinical Laboratory, Weifang People’s Hospital, 151, Guangwen Streer, Weifang, 261041 China
4 https://ror.org/021cj6z65 grid.410645.2 0000 0001 0455 0905 Department of Dermatology, The Affiliated Haici Hospital of Qingdao University, Qingdao, 266003 China
17 9 2024
17 9 2024
2024
12 10517 7 2024
9 9 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Methyltransferase-like protein is a ubiquitous enzyme-like protein in the human body, with binding domains for nucleic acids, proteins and other small molecules, and plays an important role in a variety of biological behaviours in normal organisms and diseases, characterised by the presence of a methyltransferase-like structural domain and a structurally conserved SAM-binding domain formed by the seven-stranded β-fold structure in the center of the protein. With the deepening of research, the METTL protein family has been found to be abnormally expressed in a variety of tumor diseases, and the clarification of its relationship with tumor diseases can be used as a molecular therapeutic target and has an important role in the prognosis of tumors. In this paper, we review the structure, biological process, immunotherapy, drug-targeted therapy, and markers of the METTL protein family to provide new ideas for the diagnosis and treatment of tumors.

Supplementary Information

The online version contains supplementary material available at 10.1186/s40364-024-00652-3.

Keywords

METTL protein family
Cancer progression
Biomarker
Treatment
Inhibitor
National Natural Science Foundation of China81871231 81803895 Taishan Scholars Young Experts Program, China Postdoctoral Science Foundation2021T140357 2020M682131 Shandong Province Natural Science FoundationZR2021YQ57 China Postdoctoral Science Foundation2020M682131 Youth Innovation and Technology Plan of Shandong Province2019KJK016 Science and Technology Project of Qingdao18-6-1-91-nsh issue-copyright-statement© Yumed Inc. and BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcIntroduction

Methyltransferase catalyzes the transfer of methyl to DNA, RNA, proteins and other biomolecules [1]. Methyltransferase-like (METTL) proteins are a seven-chain methyltransferase family with an S-adenosylmethionine binding domain [2]. METTL is a protein encoded by a highly conserved polygenic family and is widely found in animals and plants [3, 4]. Thirty-four members of the METTL protein family have been found in mammals, twelve of which modify DNA or RNA, fifteen modify protein residues, and six whose functions are currently unknown [5]. They are uniquely expressed in specific tissues and organs; for example, the expression level of METTL3 was significantly higher in the roots, stems, leaves, garland, petals, stamens, pistil and calyx of cotton [6]. METTL14 expression is significantly reduced in patients with retinitis pigmentosa (RP) [7]. METTL23 is closely related to Intellectual disability (ID) and fully segregates with the phenotype of ID and facial dysmorphism [8].

METTL proteins also have a broad substrate range and different species of METTL proteins are involved in different cellular biological processes, including cardiovascular disease, ophthalmic diseases, tumor progression and viral replication [9]. Impaired m [7]G tRNA modification upon METTL1 depletion resulted in decreased cell proliferation capacities of lung cancer [10]. METTL3 overexpressing mice exhibited significant myocardial hypertonicity but no accelerated dysfunction during pressure overload stress [11]. Replication of SARS-CoV-2, the agent responsible for the COVID-19 pandemic, and a seasonal human β-coronavirus HCoV-OC43, can be suppressed by depletion of METTL3 or cytoplasmic m6A reader proteins YTHDF1 and YTHDF3 [12]. The METTL protein family also plays a function in cancer progression, and seventeen members of the METTL protein family have been successively shown to have pro- or anti-cancer effects [13]. These include METTL1-9, METTL11, METTL13-18, METTL21 and METTL24. Tissue-specific METTL proteins exist in different cancers, including bladder cancer [14], hepatocellular carcinoma [15], breast cancer [16] and colorectal cancer [9]. The METTL protein family affects a variety of signaling pathways and can be used as markers of tumor development. In addition, some METTL proteins are potential therapeutic targets for tumors. To explore the effects of these drugs and their inhibitors can provide better strategies for early diagnosis, clinical treatment and prognosis of tumors.

The molecular structure of METTL protein family

The METTL protein family is a subfamily of seven β-folded chain methyltransferases in the order β3β2β1β4β5β7β6 [17]. The METTL protein family consists of an N-terminal RNA-binding structural domain, a methyltransferase domain (MTD), and a C-terminal VCR-conserved structural domain [18]. The RNA-binding structural domain consists of approximately the first 40 or so amino acids of the N-terminal end, and includes multiple positively charged amino acid residues [19]. In terms of spatial structure, these amino acid residues together form a groove for accommodating RNA that can anchor the target RNA and provide spatial conditions for its methyl transfer [20]. The positively charged amino acid residues at the entrance form a “pocket” structure that facilitates the binding and methylation of the target RNA by the METTL protein [21](Fig. 1).

Members of the METTL family have a conserved S-adenosylmethionine (SAM) binding structural domain that methylates not only proteins, but also nucleotides and other small molecule metabolites [22, 23]. The methyltransferase structural domain contains an ordered polypeptide loop, an NPPF motif, and a disordered loop. The ordered polypeptide loop is an equilibrium sensor for intracellular SAM molecules [18, 24]. Under different SAM concentrations, the ordered polypeptide ring will change its own conformation and regulate the methylation modification efficiency of METTL proteins [25].The NPPF motif, as the active site of MTD, can prompt the substrate RNA to bind with SAM at the pocket and induce the substrate RNA to undergo methylation [26]. The charge state of the disordered loop can regulate the binding of METTL protein to RNA, which in turn affects the methylation of the target RNA [23]. When the negatively charged amino acid residues of the disordered ring are mutated to positively charged amino acid residues, the methyl modification function of the METTL protein remains unchanged [23]. However, when some of the positively charged amino acid residues of the loop were mutated to negatively charged, the binding ability of the METTL protein to RNA was reduced, which might be related to the charge repulsion of RNA [27]. The above three functional structures regulate METTL protein methyltransferase activity in their own unique ways [28].

The VCR structural domain, also known as the conserved region, consists of VCR1, VCR2 and a disordered region [28]. At present, the function and mechanism of the VCR structural domain have not been fully elucidated [29]. Some studies have shown that the VCR structural domain can regulate the splicing of RNA and the methylation process of its target RNAs, but it is worthwhile to further explore whether the VCR structural domain also has other functions [23].

Fig. 1 The molecular structure of METTL protein. METTL protein family is a subfamily of seven β-folded chain methyltransferases in the order β3β2β1β4β5β7β6. METTL protein family consists of an N-terminal RNA-binding structural domain, a methyltransferase domain (MTD), and a C-terminal VCR-conserved structural domain. Figure A is the figure structure of METTL9, figure B is the three-dimensional structure of METTL9, corresponding to figure A

The role of METTL protein family in cancer progression

The biological process of cancer includes the cascade reaction process of cancer cells escaping from the primary site, penetrating blood vessels, circulating dissemination, and distal colonization [30, 31]. Existing evidence shows that METTL protein family regulates tumor cell proliferation, cell cycle, invasion, migration, autophagy and apoptosis through signaling pathways. In addition, members of the METTL protein family have different expression patterns in different cancers (Fig. 2). Although members of the METTL protein family are conserved in structure, they play different regulatory roles in tumorigenetic development, respectively promoting or inhibiting the tumorigenetic development (Table 1).

Fig. 2 The distribution of METTL protein family members in different cancers

The role of METTL protein family in cell proliferation

The METTL protein family can promote or inhibit tumor proliferation by affecting cell membrane, cytoskeleton formation and signaling pathway [17]. In osteosarcoma, METTL1 is highly expressed in osteosarcoma and correlates with poor patient prognosis. Knockdown of METTL1 results in reduced levels of tRNA m7G modification and impairs osteosarcoma proliferation in vitro and in vivo [32]. METTL1 is highly expressed in nasopharyngeal carcinoma, and METTL1 promotes the proliferation of nasopharyngeal carcinoma cells by upregulating the Wnt/β-catenin signaling pathway [33]. METTL3 knockdown significantly inhibited the growth of gastric cancer(GC), and METTL3 acted as a methyltransferase to regulate the expression of genes related to the TGF-β/smad pathway, especially METTL3 modifies Smad3 mRNA through m6A [34]. Similarly, in bladder cancer, METTL3 exerts oncogenic effects by interacting with DGCR8 and positively regulating the pri-miR221/222 process in an m6a-dependent manner [35]. METTL4 is highly expressed in upper tract urothelial cancer and METTL4 induces nuclear 6 mA modification during tumor metastasis [36]. METTL5 regulates hepatocellular carcinoma (HCC) proliferation through numerous pro-oncogenic USP5-c-Myc signaling cascades [37]. METTL6 catalyzes the formation of 3-methylcytidine at the C32 site of a specific serine tRNA heteroreceptor, and deletion of METTL6 leads to changes in ribosome occupancy and RNA levels, as well as impaired pluripotency in HCC [38]. METTL13 promoted GC cell growth through an eEF1A/HN1L positive feedback loop [39]. In addition, METTL13 also promoted HCC cell proliferation by upregulating TCF3 and ZEB1 [40].

Conversely, METTL14 is downregulated in GC, and METTL14 overexpression inhibits the PI3K/AKT/mTOR pathway to suppress GC proliferation [41]. METTL14 is downregulated in bladder cancer tissues. METTL14 also inhibits the proliferation of bladder cancer cells [42]. Knockout of METTL14 decreased the m6A level of lnc RNA XIST, reduced the recognition and degradation of XIST by YTHDF2, and promoted the expression of XIST and the proliferative capacity of colorectal cancer [43]. METTL16 activates the p21 signalling pathway by m6A modification and inhibits the proliferation of pancreatic ductal adenocarcinoma cells [44]. In addition, METTL16 can inhibit the translation of DVL2 mRNA through m6A modification, thereby regulating the Wnt/β-catenin signalling pathway and inhibiting the proliferation of pancreatic ductal adenocarcinoma cells [45]. In summary, the METTL protein family regulates tumor proliferation by targeting the stability of the internal structure of RNA methylation as well as multiple signaling pathways in a wide range of malignant tumors, including HCC and GC, and different members of the METTL protein family can play opposite roles in the same tumor.

The role of METTL protein family in cell cycle

Cell cycle regulation is a cornerstone of tumor development. Methylation modifications directly influence tumor cell growth dynamics by precisely regulating RNA behaviour [46]. The METTL protein family plays critical roles in cell cycle regulation in a complex manner. METTL1 knockdown suppressed colorectal cancer growth and G1/S phase transition and interacted with checkpoint kinase 2 and suppress its protein expression [47]. In osteosarcoma, knockdown of METTL3 decreases mRNA and protein levels of DRG1, which further leads to G2/M phase cell cycle arrest and inhibits osteosarcoma cell proliferation [48]. METTL7B expression is elevated in lung cancer, and deletion of METTL7B significantly reduces cyclin D1, a key regulator of the G1/S transition, leading to G0/G1 arrest and inhibition of lung cancer proliferation [49]. METTL16 upregulates cyclin D1 expression by enhancing cyclin D1 mRNA stability through m6A modification, which in turn accelerates the G1/S phase transition to promote gastric cancer cell proliferation [50]. Elevated METTL18 expression level could activate the G2/M checkpoint, KRAS signaling pathway and mitotic spindle, and knockdown of METTL18 significantly inhibited the proliferation of HCC cells [51]. The METTL protein family plays an important role in biological processes such as cytoskeletal reorganization as well as cell cycle regulation by methylating relevant substrates itself and interacting with multiple signaling pathways. As cell cycle regulators, the METTL family of proteins has only just begun to be studied.

The role of METTL protein family in invasion and metastasis

Numerous studies have confirmed that the most common cause of poor clinical outcomes in malignant tumors is recurrence and metastasis, and the vast majority of tumors undergo EMT during tumor progression, allowing tumor cells to acquire infiltrative and metastatic properties during progression, accelerating the formation of malignant tumors and allowing for increased invasive metastatic capacity [46, 52]. Increasing evidence has elucidated the vital role of the METTL protein family in cancer invasion and metastasis. METTL protein family regulates cancer invasion and metastasis in multiple ways (Fig. 3). First, METTL protein family regulates EMT to promote tumor invasion and metastasis. METTL1 was highly expressed in bladder cancer, and its level was correlated with poor patient prognosis. Silencing METTL1 suppresses the migration and invasion of bladder cancer cells in vitro and in vivo [14]. In gliomas, the expression of METTL3 was significantly downregulated in tumor tissues compared to adjacent normal tissues. Down-regulation of METTL3 enhances the ability of the PI3K/AKT pathway to promote glioma migration and invasion [53]. In breast cancer, METTL3 inhibits E-cadherin expression through m6A modification of EZH2, thereby inducing EMT to promote tumor invasion and metastasis [54]. METTL8 expression is elevated in breast cancer, and knockdown of METTL8 inhibits tumor cell growth and strongly blocks tumor cell migration [55]. METTL13 is lowly expressed in renal cell carcinoma, and knockdown of METTL13 promotes the PI3K/AKT/mTOR/HIF-1α pathway leading to migratory ability and invasiveness of renal cell carcinoma cells as well as elevated Vimentin and N-cadherin [56]. Second, the METTL protein family regulates angiogenesis to promote tumor invasion and metastasis. In bladder cancer, METTL3 deletion resulted in reduced m6A abundance in specific regions of tyrosine kinase endothelial (TEK) and VEGF-A mRNA and decreased levels of TEK and VEGF-A mRNA and protein [57].

Finally, the METTL protein family regulates tumor invasion and metastasis by mediating methylation modifications. METTL1 knockout markedly reduced the proliferation, migration, and invasive ability of head and neck squamous cell carcinoma cells, and by decreasing the level of m7G tRNA modification inhibited oncogenic gene translation and PI3K/AKT/mTOR signaling pathway [58]. In colorectal cancer, METTL3 promotes the expression of circ1662 by m6A modification of circ1662 through binding to its flanking strand, while circ1662 can regulate SMAD3 expression by accelerating the nuclear localization of YAP1, which ultimately promotes invasive metastasis of colorectal cancer [59]. Deletion of METTL5 affects the modification of 18 S rRNA m6A, which hinders ribosome synthesis and inhibits translation of G-tetraploid-rich mRNAs in the transforming growth factor TGF-β pathway, inhibiting intrahepatic cholangiocarcinoma invasion and migration [60]. The expression of circ-METTL9 was significantly up-regulated in colorectal cancer tissues and significantly elevated in patients with advanced colorectal cancer tumors. Overexpression of circ-METTL9 promotes colorectal cancer cell proliferation and migration in vitro, as well as colorectal cancer tumor growth and metastasis in vivo [9]. METTL14 leads to a decrease in m6A methylation and activation of the AKT pathway, which promotes the proliferation and migration of endometrial cancer cells. The increase in AKT activity is dependent on a decrease in PHLPP2 expression and an increase in mTORC2 expression. METTL14 leads to a decrease in m6A methylation and activation of the AKT pathway, which promotes the proliferation and migration of endometrial cancer cells. The increase in AKT activity is dependent on a decrease in PHLPP2 expression and an increase in mTORC2 expression [61]. METTL16 reduced the m6A methylation level of iron-dead GPX4 mRNA and significantly promoted the degradation of GPX4 mRNA, suggesting that METTL16 enhances the expression level of GPX4 through m6A modification, and thus inhibits iron-death to promote the proliferation of breast cancer cells [62]. In colorectal cancer, METTL17 inhibition disrupts mitochondrial function, energy metabolism, and enhances intracellular and mitochondrial lipid peroxidation and ROS levels. In addition, METTL17 inhibition significantly reduced mitochondrial RNA methylation, including m4C, m5C, m3C, m7G, and m6A, resulting in impaired translation of mitochondrial protein-coding genes [63]. Although the role of METTL proteins in tumor development has been extensively studied, the molecular mechanism of their regulation of tumor invasion and metastasis still needs to be further clarified. Elucidating the molecular mechanisms of METTL proteins in tumor invasion and metastasis will be beneficial to tumor therapy.

Fig. 3 Signaling pathways of METTL protein family regulating tumor cell invasion and metastasis. The METTL protein family has a dual role in cancer proliferation. METTL1, METTL5, and METTL14 promote cancer proliferation, and conversely, METTL3, METTL8 and METTL13 inhibit cancer proliferation

The role of METTL protein family in cell apoptosis

The METTL family of proteins is closely related to tumors, and its function in promoting or inhibiting apoptosis has led to its importance in the diagnosis and treatment of malignant tumors. METTL1 is significantly upregulated in advanced neuroblastoma, knockdown of METTL1 would result in a significant increase in apoptosis of neuroblastoma cells [64]. METTL3 mediated the elevation of COL10A1 expression, promoted its mRNA m6A modification, promoted ROS content, and inhibited the production of SOD and GPX, thereby accelerating the growth and inhibiting the apoptosis of lung squamous cell carcinoma [65]. METTL5 expression is elevated in uterine corpus endometrial carcinoma, and uterine corpus endometrial carcinoma patients with high METTL5 expression have a poorer prognosis. Knockdown of METTL5 decreased CEA, CA199, CA153, HE4 protein levels and increased apoptosis [66]. The expression of METTL14 was higher in pancreatic cancer tissues than in non-tumor tissues, and knockdown of METT14 promoted apoptosis by reducing the expression levels of AMPKα, ERK1/2 [67]. METTL15 expression is up-regulated in lung cancer tissues and cells. METTL15 silencing inhibits lung cancer cell proliferation, colony formation, invasion, immune escape and promotes apoptosis [68]. In lung cancer, METTL16 deficiency prevents GCN2 protein synthesis, leading to reduced expression of ATF4 in a GCN2- eIF2α-dependent manner. Reduced ATF4 further reduces expression of the apoptosis receptor protein DR5. Meanwhile, METTL16 deficiency directly impeded the synthesis of FADD and DR5 proteins, thereby impairing apoptosis and promoting cancer cell survival [69]. Increasing understanding of the regulation of complex signaling pathways within the METTL family of proteins in tumors, particularly apoptosis, allows for more rational design of anti-cancer strategies.

The role of METTL protein family in cell autophagy

Autophagy is lysosome-mediated cellular self-digestion, which constitutes a cyclic dynamic pathway of damaged organelles and long-lived proteins, and plays a major role in the body’s internal environmental homeostasis and tumorigenic mechanisms to ensure that cells have access to sustainably utilized energy under stress conditions such as nutrient deficiencies and the tumor microenvironment, and in this way maintain homeostasis and viability in the body [70]. In small cell lung cancer, METTL3 induces m6A methylation of DCP2, leading to DCP2 degradation and promoting mitochondrial autophagy through the Pink1-Parkin pathway [71]. METTL14 is up-regulated in pancreatic cancer and down-regulation of METTL14 improves autophagy through mTOR signaling-dependent pathways [67]. METTL14 enhances RB1CC1 expression after transcription in an m6A-IGF2BP2-dependent manner, thereby affecting autophagy and progression of oral squamous cell carcinoma. In vitro, knockdown of METTL14 significantly inhibited autophagy and promoted malignant progression, and in vivo promoted tumor growth and metastasis [72]. METTL16 significantly inhibits bladder cancer cell proliferation through the HIF-2α-METTL16- PMEPA1 autophagy axis in an m6A manner [73]. The METTL protein family will surely bring new hope for cancer treatment by regulating the powerful role of autophagy in tumor formation, growth and metastasis, giving it the regenerative ability to inhibit tumor growth.

Table 1 The role of the METTL protein family in cancer progression

Member	Cancer type	Type cell	Expression patterns	Effect	Ref	
METTL1	Osteosarcoma	Hos and 143B cells	Protein	METTL1 is elevated in osteosarcoma and correlated with poor prognosis	[32]	
Nasopharyngeal carcinoma	NP-69, 5–8 F and 6-10B cells	mRNA and Protein	Promoting the proliferation of nasopharyngeal carcinoma	[33]	
Colorectal cancer	HCT116 and RKO cells	Protein	METTL1 knockdown suppressed G1/S phase transition	[47]	
Bladder cancer	5637, J82, T24 and UM-UC-3 cells	mRNA and Protein	Inhibiting the migration and invasion of bladder cancer	[14]	
Head and neck squamous cell carcinoma	UM1, SCC9 and SCC25	mRNA and Protein	Inhibiting glioma migration and invasion	[58]	
Neuroblastoma	BE2C	Protein	knockdown of METTL1 would result in a significant increase in apoptosis of neuroblastoma	[64]	
METTL3	Gastric cancer	GES-1, MGC803, MNK45, and SGC7901 cells	mRNA and Protein	METTL3 knockdown significantly inhibited the growth of GC	[34]	
Bladder cancer	EJ and T24 cells	mRNA and Protein	Promoting the proliferation of bladder cancer	[35]	
Osteosarcoma	Saos-2, U2OS, MG63 and 143B cells	mRNA and Protein	Leading to G2/M phase cell cycle arrest	[48]	
Gliomas	KS-1	mRNA and Protein	Down-regulation of METTL3 promotes glioma migration and invasion	[53]	
Breast cancer	MCF10A, MCF-7 and BT474	mRNA and Protein	Promoting tumor invasion and metastasis	[54]	
Colorectal cancer	HCT116 and SW480 cells	mRNA and Protein	Promoting invasion and metastasis of colorectal cancer	[59]	
Lung squamous cell carcinoma	SW900 and LOU-NH91 cells	Protein	Inhibiting the apoptosis of lung squamous cell carcinoma	[65]	
Small cell lung cancer	H69 and H69AR cells	mRNA and Protein	METTL3 promoting mitochondrial autophagy	[71]	
METTL4	Upper tract urothelial cancer	KTCC28M cell	mRNA and Protein	METTL4 is highly expressed in upper tract urothelial cancer	[36]	
METTL5	Hepatocellular carcinoma	Huh7, HCCLM3, SNU182, Hep3B, and HepG2 cells	mRNA and Protein	Promoting the proliferation of HCC	[37]	
Intrahepatic cholangiocarcinoma	HCCC-9810 and QBC-939 cells	mRNA and Protein	Promoting the invasion and metastasis of ICC	[60]	
Uterine corpus endometrial carcinoma	KLE cells, RL952 cells, Ishikawa and ECC-1 cells	Protein	Knockdown of METTL5 increased apoptosis in uterine corpus endometrial carcinoma	[66]	
METTL6	Hepatocellular carcinoma	HepG2 cell	mRNA	Knockout of METTL6 inhibits the proliferation ability of HCC	[38]	
METTL7B	Lung cancer	A549 and PC-9	mRNA and Protein	Knockdown of METTL7B leading to G0/G1 arrest and inhibition of lung cancer proliferation	[49]	
METTL8	Breast cancer	MDA-MB-231 and MCF-7	mRNA and Protein	Promoting tumor cell growth	[55]	
METTL9	Colorectal cancer	Caco2, HCT116, SW480, SW620, RKO, LoVo, DLD-1 and HT-29 cell	mRNA and Protein	Overexpression of circ-METTL9 promotes colorectal cancer cell proliferation and migration	[9]	
METTL13	Gastric cancer	AGS, MKN28 and MGC803 cells	Protein	Promoting GC cell proliferation	[39]	
Hepatocellular carcinoma	HCCLM6, BEL-7402 and QGY-7703 cells	Protein	Promoting HCC cell proliferation	[40]	
Renal cell carcinoma	786-O, 769-P, OS-RC-2, Caki-1 and ACHN cells	mRNA and Protein	knockdown of METTL13 promotes Renal cell carcinoma migration	[56]	
METTL14	Gastric cancer	SGC-7901	mRNA and Protein	Suppressing GC proliferation	[41]	
Bladder cancer	U5637 and T24T cells	mRNA and Protein	Inhibiting the proliferation of bladder cancer	[42]	
Colorectal cancer	SW480, SW620, HCT116, LoVo and HT29 cells	mRNA and Protein	Knockout of METTL14 promoted the proliferative capacity of colorectal cancer	[43]	
Endometrial cancer	HEC-1-A	mRNA and Protein	Promoting the proliferation and migration of endometrial cancer	[61]	
Pancreatic cancer	PANC-1 and CFPAC-1 cells	mRNA and Protein	Promoting apoptosis of pancreatic cancer	[67]	
Oral squamous cell carcinoma	CAL33 and HSC3 cells	mRNA and Protein	Knockdown of METTL14 inhibits autophagy	[72]	
METTL15	Lung cancer	H1299	Protein	Promoting apoptosis of lung cancer	[68]	
METTL16	Pancreatic ductal adenocarcinoma	PANC-1, SW-1990, BxPC-3 and AsPC-1 cells	mRNA and Protein	Inhibiting the proliferation of pancreatic ductal adenocarcinoma	[44, 45]	
Gastric cancer	AGS, MGC803, SNU719, HGC27, SGC7901 and MKN28	mRNA and Protein	Accelerating the G1/S phase transition to promote gastric cancer proliferation	[50]	
Breast cancer	MCF-10 A, MDA-MB-231, MDA-MB-468, MDA-MB-453 and MCF-7 cells	mRNA and Protein	Promoting breast cancer cell proliferation by inhibiting iron death	[62]	
Lung cancer	A549 and H1299 cells	mRNA and Protein	METTL16 deficiency impairs apoptosis and promotes cancer cell survival	[69]	
Bladder cancer	T24, RT4, UMUC3, TCC, J82, 253 J and BIU87	Protein	Inhibiting bladder cancer cell proliferation	[73]	
METTL17	Colorectal cancer	SW620	mRNA and Protein	Inhibition of METTL17 disrupts mitochondrial function and energy metabolism	[63]	
METTL18	Hepatocellular carcinoma	HepG2, M97H, LM3, Bel7402, SK-HEP1 and Huh7 cells	Protein	Activating the G2/M checkpoint	[51]	

The role of METTL protein family in tumor immunity

The tumor microenvironment (TME) is a heterogeneous ecosystem that includes non-cellular components such as cancer cells, immune cells, stromal cells, and extracellular matrix, all of which play key roles in tumorigenesis and progression as well as in modulating the tumor’s response to immunotherapies [74–76]. The TME has been found to have the dual potential to inhibit or promote cancer. During the early stages of tumor growth, infiltrating immune cells and associated stromal components are recruited and activated by tumor cells to establish anti-tumor TME and prevent tumor formation and progression [76–78]. However, sustained immune stimulation induces depletion or remodeling of effector cells, ultimately leading to immunosuppressive TME [79]. Therefore, eliminating the suppressive effects and restoring the innate anti-tumor capacity of the immune system represent promising strategies for cancer therapy [74].

Currently, the link between epitranscriptomic abnormalities and cancer immune escape is gradually being revealed. Targeting RNA epigenetic dysregulation for therapeutic purposes can reprogram TME to improve cancer immunotherapy [80]. The METTL protein family regulates phenomena such as m6A modification of mRNAs as well as the m7G of tRNAs, which play important roles in RNA epigenetic processes. Numerous studies have confirmed that the METTL protein family plays a regulatory role in a variety of immune-related pathways. METTL3 can positively regulate the activation of the NF-κB pathway by TRAF 6, which in turn triggers an LPS-mediated inflammatory response [81]. METTL14 promotes the process of FOXO1 methylation, which in turn induces endothelial inflammation [82]. METTL16, which is evolutionarily conserved, has been found to play a major role in the small yellow croaker (a scleractinian fish) was found to inhibit antiviral immune response through m6A methylation modification [83]. Meanwhile, the METTL family of proteins has been shown to regulate immune cell activity and thereby modulate the immune response-cell activation is regulated by a variety of immunomodulatory proteins. CD4+T-cell activation is mediated by the binding of peptide major histocompatibility complexes (pMHCs) on the surface of antigen-presenting cells (APCs) to the T-cell receptor (TCR). Following pMHC-TCR interaction and CD4+ T cell activation, co-stimulatory molecules such as CD28, inducible T cell co stimulator (ICOS) and CD40 ligand (CD40L) translocate to the surface of CD4+ T cells. Together, these co-stimulatory and co-inhibitory molecules regulate the duration and intensity of TCR-mediated signaling to promote an optimal immune response. Given the complexity of the immune response, precise regulation of the expression of co-stimulatory molecules, among other processes, is essential for a well-coordinated T cell response. Among other things, protein-mediated m6A modifications such as METTL3 regulate the expression of CD 40 L in human CD4+ lymphocytes and modulate CD4+ lymphocyte activation. However, CD40L is not the only co-stimulatory molecule expressed on activated CD4+ T cells, and co-inhibitory molecules contribute to the regulation of immune response. Studies of the mechanisms associated with m6A modifications in CD4+ lymphocytes can contribute to the clinical management of autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and Scheuglen’s syndrome [84]. Regulatory T cells (Tregs) are heterogeneous subpopulations of helper T (Th) cells, which can be classified into thymic Tregs (tTreg) (originating from the thymus) as well as peripheral Tregs (pTreg) (originating from peripheral tissues) by constitutive expression of the transcription factor FoxP3, and play an important role in immune homeostasis by suppressing self-reactive effector T cells (Teff) [85, 86]. Therefore, therapies based on iTregs (regulatory T cells induced in vitro) have received increasing attention for their potential to treat autoimmune diseases and prevent transplant rejection. However, Tregs cells constitute only 10–15% of the CD4+T cell population; and iTregs are unable to maintain stable FoxP3 expression and rapidly lose their inhibitory activity, which are two major limitations for the clinical application of Tregs. Liu et al. demonstrated that METTL14 could regulate the stability and function of Tregs cells. The specific mechanism is that METTL14 defects in iTregs activate the mTOR-dependent pathway, increase p-mTOR and p-p70S6K, disrupt iTregs polarization, and downregulate FoxP3 expression. Meanwhile, inflammatory cytokines such as IFN-γ and IL-17a were up-regulated in cultured iTregs. METTL14 defects significantly impaired the inhibitory function of iTregs in vivo and in vitro, which revealed that METTL14 is a positive regulator of iTregs [87]. We review the mechanism of METTL protein family involvement in tumor immunity and summarize the role played by METTL protein family in immunotherapy in the following paper (Fig. 4). The relationship between METTL protein family and tumor immunity has received much attention and is a very promising research direction for the future.

Fig. 4 METTL protein family-associated tumor immune microenvironment. METTL3 can positively regulate the activation of the NF-κB pathway by TRAF 6 and METTL14 promotes the process of FOXO1 methylation, which in turn triggers an inflammatory response. METTL16 was found to inhibit antiviral immune response through m6A methylation modification. T-cell activation is regulated by a variety of immunomodulatory proteins. ICOS and CD40L are translocated to the surface of CD4+T cells. METTL3 regulate the expression of CD40L in human CD4+ lymphocytes and modulate CD4+ lymphocyte activation. Tregs are heterogeneous subpopulations of Th cells, which can be classified into tTreg as well as pTreg by constitutive expression of the transcription factor FoxP3 and play an important role in immune homeostasis by suppressing Teff

The role of METTL1 in tumor immunity

There is a significant correlation between METTL1 and regulatory T cell content in BRCA, KIRP, KIRC, LUAD, LIHC, PRAD and SARC. In TGCT, METTL1 was negatively correlated with resting mast cell, M2 macrophage, and M0 macrophage content, and showed significant positive correlations in activation memory CD4+T cells, CD8+T cells, follicular helper T cells, and naïve B cells. For multiple immunosuppressive agents, KDR and CD274 showed the most significant negative correlation with METTL1 in almost all cancers. Among MHC molecules and immunostimulators, most biomarkers were negatively correlated with METTL1, except for KIRP, LGG and TGCT. Three ICB therapeutic biomarkers (MSI, TMB, and CD274) showed significant correlation with METTL1 in a few cancers. METTL1 was negatively correlated with MSI and TMB in COAD but positively correlated with markers of HNSC, KICH, PRAD, and STAD, suggesting that METTL1 may have an impact on ICB therapeutic response in cancers such as HNSC. response. ICB treatment response was correlated with METTL1. METTL1 expression in the no/limited response group was significantly lower than that in the anti-PD-L1 cohort response group, suggesting that METTL1 expression may reflect the sensitivity to ICB therapy, but the difference was not significant. METTL1 may be effective in the treatment of HNSC and other cancers through the targeting of other immune checkpoints, including the T-cell Ig and ITIM structural domains (TIGIT), or the cytotoxic T lymphocyte-associated protein 4 (CTLA-4). protein 4 (CTLA-4)) to affect the response to ICB therapy, which requires further experimental evidence [88].

The role of METTL3 in tumor immunity

METTL3 has been more studied in tumor immunity. JNK signaling promotes immune escape from BCa by regulating METTL3-mediated m6A modification of programmed death ligand 1 (PD-L1) [16]. In vitro and in vivo, activated JNK signaling enriches METTL3-mediated m6 A in the 3’-UTR of PD-L1 mRNA by binding c-Jun to the METTL3 promoter, allowing PD-L1 mRNA to be recognized by the m6A reader, IGF2BP1, to mediate RNA stability and PD-L1 expression levels that This in turn resists cytotoxicity of CD8+T cells and promotes tumor immune escape. METTL3 inhibition is a promising direction for targeting immunotherapeutic resistance in bladder cancer. Smoking is a major risk factor for bladder cancer because it activates JNK signaling. However, the effect of smoking on JNK signaling activation and METTL3 expression needs to be further investigated [89]. It has also been shown that METTL3 regulates the m6A modification of PD-L1, and knockdown of METTL3 in OSCC cells inhibits the activation of CD8+ T cells [90].

PD-L1 can bind to T cell PD-1, inhibit the immune recognition function and cytotoxicity of T cells against tumor cells, and promote immune evasion and tumor growth. Therefore, ICI therapies such as anti-programmed death receptor 1 (PD-1) therapy have dramatically changed the face of cancer treatment. However, many cancer patients have a low response rate to ICI therapy, for example, in ICI therapy for CRC, the objective remission rate of Regorafenib in combination with anti-PD-1 antibody for CRC was 33%. Clinical studies have shown that ICI treatment response is positively correlated with tumor-infiltrating T-cell (TIL) levels. However, many solid tumors lack sufficient T-cell infiltration, leading to immune evasion and further progression of the tumor, highlighting the need for effective recruitment and infiltration of tumor-targeted T-cells to the tumor site. The primary mechanism of T-cell infiltration is the response of G-protein-coupled receptors to chemokines, which facilitates the activation of integrins through an inside-out signaling pathway. Integrins can bind to ECM proteins to promote dynamic cytoskeleton assembly and the formation of filamentous pseudopods, invasive pseudopods, and pseudopod bodies, which allow T cells to move along collagen in the ECM with pseudopod amoeboid motility. Skin cancer extracellular acidification inhibits METTL3-mediated m6A modification and the level of its downstream target integrin β1 (ITGβ1), thereby suppressing T cell migration. This suggests that METTL3-m6A is an upstream epigenetic regulator in response to acidic TME and plays a key role in regulating T cell infiltration as well as T cell anticancer activity. Down-regulation of METTL3 activity or enhancement of ITGβ1 expression to increase T-cell infiltration within acidic TME are potential ways to improve the therapeutic efficacy of ICB [91]. However, another study showed that lactate accumulation in TME mediated K281 and K345 lactoylation in the zinc finger structural domain of METTL3 caused significant upregulation of METTL3 in CRC-infiltrating myeloid cells, which enhanced the immunosuppressive activity of tumor-infiltrating myeloid cells through the lactoylation-METTL3-m6A-JAK/STAT 3 axis and was associated with a poor prognosis in CRC patients. Therefore, the clinical application of METTL3 inhibitors is expected to have beneficial effects on CRC immunotherapy [92]. The above also confirms the complexity of METTL3 function in tumor ICI therapy.

Immunosuppression is a malignant tumor phenotype triggered by the accumulation of immunosuppressive cells. Immunosuppressive cells include myeloid-derived suppressor cells (MDSCs) and tumor-derived cytokines. MDSCs, of which there are two types, G-MDSCs and monocyte MDSCs, can strongly inhibit the antitumor activity of T cells and natural killer (NK) cells (especially G-MDSCs), impair antitumor immunity and trigger immune checkpoint inhibitor (ICI) resistance. Therefore, blocking MSDCs is a potential approach to improve the outcome of ICI therapy in patients with advanced CRC. METTL3 can promote colorectal carcinogenesis by inhibiting anti-tumor immunity through targeting the m6A-BHLHE41-CXCL1 axis. Down-regulation of METTL3 would reduce MDSC accumulation through the m6 A-BHLHE 41-CXCL1 /CXCR 2 axis to maintain the activation and proliferation of CD4+ T-cells and CD8+ T-cells, which play an inhibitory role in CRC. Meanwhile, depletion of MDSC by anti-Gr-1 antibody eliminated the tumor-promoting effect of METTL3 in vivo. The combination of METTL3 inhibition and anti-PD-1 is an effective direction for MSDC-blocking CRC therapy [93](Fig. 5).

Fig. 5 METTL3 significantly inhibited the proliferation of tumor cells in tumor microenvironment. In TGCT, METTL1 was negatively correlated with resting mast cell, M2 macrophage, and M0 macrophage content, and showed significant positive correlations in activation memory CD4+T cells, CD8+T cells, follicular helper T cells, and naive B cells. In vitro and in vivo, activated JNK signaling enriches METTL3-mediated m6 A in the 3’-UTR of PD-L1 mRNA, allowing PD-L1 mRNA to be recognized by the m6A reader, IGF2BP1, to mediate RNA stability and PD-L1 expression levels which in turn resists cytotoxicity of CD8+T cells and promotes tumor immune escape. Integrins can bind to ECM to allow T cells to move along collagen in the ECM with pseudopod amoeboid motility. Skin cancer extracellular acidification inhibits METTL3-mediated m6A modification and the level of its downstream target ITGβ1, thereby suppressing T cell migration. However, K281 and K345 lactoylation caused significant upregulation of METTL3 in CRC-infiltrating myeloid cells, which enhanced the immunosuppressive activity of tumor-infiltrating myeloid cells through the lactoylation-METTL3-m6A-JAK/STAT3 axis. METTL3 can promote colorectal carcinogenesis by inhibiting anti-tumor immunity through targeting the m6A-BHLHE41-CXCL1 axis. Down-regulation of METTL3 would reduce MDSC accumulation to maintain the activation and proliferation of CD4+T-cells and CD8+T-cells

The role of METTL7A in tumor immunity

METTL7A plays an important role in tumor immunity. Multiple bioinformatics analyses have revealed the role played by METTL7A in tumor immunity from different perspectives. GSEA-GO analyses showed that METTL7A may influence tumor pathogenesis through leukocyte activation and adaptive immune response. GO and KEGG analyses revealed that differentially expressed genes in patients with high METTL7A expression and low METTL7A expression play an important role in antigen processing and presentation as well as adaptive immune response, suggesting that METTL7A may play a role in immune response and immune checkpoint inhibitor therapy. In immunotherapy, both tumor mutational load (TMB) and microsatellite instability (MSI) are important biomarkers of response to immunotherapy. In LUAD, METTL7A was negatively correlated with both TMB and MSI, suggesting that METTL7A is important in maintaining genomic stability. Meanwhile, METTL7A was negatively correlated with MSI in COAD and positively correlated with MSI in READ.METTL7A was positively correlated with immune scores in 12 cancers, and negatively correlated with immune scores in BLCA, CESC, LIHC, KIRC, and THCA.METTL7A is highly expressed in immune cells and is involved in immune cell infiltration. cell infiltration. Specifically, METTL7A showed increasing correlation with invasive immune cells such as B cells, CD4 + T cells and mast cells, and negative correlation with M0 macrophages, activated mast cells, activated memory CD4 + T cells, CD8 + T cells and follicular helper T cells in several tumors. In addition, METTL7A showed similar correlation with genes related to cancer immunotherapy [94]. METTL7B was also significantly associated with tumor immune cell infiltration [95].

The role of METTL11B in tumor immunity

Cibersort analysis showed that METTL11B could affect immune cells such as Th17 cells, Th1 cells, Tgd cells, Tfhs, TEM, TCN, CD 56 bright NK cells, T helper cells, neutrophils, mast cells, NK cells, macrophages, IDCs, eosinophils, and DCs (all P < 0.001); Meanwhile, METTL11B also interacted with MSI-related molecules (PMS 1, MSH 6, PMS 2, MLH 1 and MLH 3). This suggests that METTL11B is closely associated with immune infiltration in CRC, but its specific mechanism needs to be proved by further experiments [76].

The role of other members of the METTL protein family in tumor immunity

Inhibition of METTL14-mediated m6A mRNA modification improves the efficacy of anti-PD-1 therapy in CRC. Inhibition of METTL14 not only promotes the proliferation and accumulation of cytotoxic tumor-infiltrating CD8 + T cells, but also induces the secretion of IFNC, CXCL9, and CXCL 10, which enhances the efficacy of immunotherapy and inhibits cancer proliferation [96].

In CRC tissues and cell lines, decreased METTL16 expression and increased PD-L1 expression enhanced the process of CRC cell proliferation, migration and invasion. Overexpression of METTL16 reduces PD-L1 expression in CRC cells by inducing m6A modification and PD-L1 RNA degradation, which is an effective target for CRC immunotherapy [97].

METTL24 can participate in immune processes such as cytokine binding, NF-κB binding, MHC protein complexes and interleukin-12 action. Meanwhile, METTL24 is associated with some immune checkpoints, cytokines, chemokines and chemokine receptors. The level of immune cell infiltration in KIRC in 10 and the survival rate of patients with different immune infiltrations were also correlated with METTL24 [98].

The role of METTL protein family as a biomarker in cancer diagnosis

The role of METTL1 as a biomarker in cancer diagnosis

GSEA analysis showed that genes of proliferation- and metastasis-related pathways were more likely to be enriched in high METTL1 expression cohorts in KIRC, LGG, and LIHC, demonstrating that METTL1 is a poor patient prognosis biomarker in these cancers and can be used to assess patient survival [88]. tRNA N7 methylguanosine (m7G) methyltransferase complex components METTL1 and WD Repeat Domain 4 (WDR 4) expression levels were significantly elevated in human lung cancer samples and negatively correlated with patient prognosis [99].METTL1 and WDR 4 proteins were significantly up-regulated in HCC, which promotes HCC cell proliferation, migration, and invasion, and were negatively correlated with HCC patient survival at levels associated with a poor prognosis for HCC [100]. Under the regulation of PKB and ribosomal S6 kinase [101], METTL1 can catalyze 7-methylguanosine (m7G) modification in microRNAs and tRNAs, and exerts pro-HCC activity through the PTEN/AKT signaling pathway by inhibiting PTEN signaling. METTL1 induces the expression of NANOG and KLF4 [102], the latter Both were shown to be regulated by PTEN, and knockdown of NANOG downregulated the METTL1-mediated HCC malignant phenotype. However, the specific mechanism by which METTL1 regulates PTEN and whether METTL1 is involved in the stemness of HCC through PTEN-regulated NANOG requires further investigation [103]. upregulation of METTL1 has been associated with poor prognosis and HCC progression in HCC patients [102–104]. Through an unbiased proteomic screen of parental and lenvatinib-resistant HCC cells, two key tRNA m7 G methyltransferase complex components, METTL1 and WDR 4, were found to be significantly up-regulated in Lenvatinib-resistant HCC cells, with METTL1 being the catalytic enzyme and WDR 4 acting as a regulator. By testing HCC organoids for Lenvatinib sensitivity, high expression of METTL1 with WDR 4 proved to be more tolerant to Lenvatinib. Meanwhile, patients with low levels of METTL1 and WDR4 had a better prognosis for Lenvatinib treatment. Therefore, as a biomarker for predicting the efficacy of Lenvatinib, METTL1/WDR4 could be used for personalized treatment of HCC [105]. METTL1, which is highly expressed in HNSCC, promotes the development and malignancy of HNSCC by up-regulating the translation of overall mRNAs including the PI3K/AKT/mTOR signaling pathway, and has been found to alter the immune landscape, which is associated with the poor prognosis in HNSCC patients [106]. METTL1 is highly expressed in enamel cell tumors (AM) and significantly correlated with postoperative recurrence.METTL1 can promote invasive growth of AM through the mitogen-activated protein kinase (MAPK) signaling pathway, and is a poor prognostic factor for AM [107]. METTL1 is significantly up-regulated in esophageal squamous cell carcinoma, and its mediated tRNA m7 G modification promotes malignant progression of esophageal squamous cell carcinoma through the RPTOR/ULK 1/autophagy axis, and its high expression is associated with poor prognosis of patients [108]. mETTL1 expression is significantly higher in gliomas than in paracancerous tissues in both normal brain tissues and glioma tissues, and the expression of METTL1 rises with the grade of glioma. mETTL1 is a potential independent prognostic risk factor, with short survival and poor prognosis in patients with high expression [109].

The role of METTL3 as a biomarker in cancer diagnosis

A meta-analysis showed that in various cancers, METTL3 carriers predicted worse OS compared to patients with lower METTL3 expression. METTL3 expression was higher in females than in males, and high METTL3 expression was associated with poorer differentiation [110]. Pan-cancer analysis showed that METTL3 expression was up-regulated in a variety of cancers, and higher METTL3 expression levels were significantly associated with poorer overall survival in ACC, KICH and LIHC, and poorer DFS in ACC, CESC, HNSC, KICH and LIHC. METTL3 has the highest potential as a biomarker in ACC, KICH and LIHC, but this needs further experimental confirmation [111].

Esophageal squamous cell carcinoma (ESCC) has a low early diagnosis rate, low 5-year survival rate of patients and poor prognosis [112, 113]. m6A was found to be up-regulated at the tissue and cellular levels in ESCC. mRNA and protein of METTL3 were found to be high in ESCC, and the level of mRNA expression was correlated with the degree of differentiation and gender of ESCC, and played a METTL3 content showed a positive correlation with the proliferation level of ESCC cells, which may promote ESCC progression by mediating m6 A modification via the p21 axis affecting the cell cycle. ROC curves showed that METTL3 had a high sensitivity and specificity for the diagnosis of ESCC (the area under the ROC curve was 0.8030, with a sensitivity of 75.00% and a specificity of 72.06%), and at the same time, METTL3 was closely associated with worse prognosis of tumor patients, proving that METTL3 is an important diagnostic marker for ESCC [114, 115]. Overexpression of METTL3 in lung cancer cells activates the PI3K/AKT/mTOR pathway and mTOR-mediated protein synthesis, promotes the proliferation and metastasis of cancer cells, and is a poor prognostic factor for lung cancer patients [116]. In the development of non-small cell lung cancer, both m6A and long chain non-coding RNAs (lncRNAs) play key regulatory roles. The specific mechanism is that METTL3 can m6A-modify the lncRNA ABHD11-AS1 to promote the proliferation of NSCLC cells with the Warburg effect [117]; METTL3 also increases the m6A level of RAC3 mRNA, which increases RAC3 mRNA stability and upregulates the cell migration of CAFs through the AKT/NF-κB pathway promotion [118], all of which are closely associated with poor prognosis of NSCLC patients.METTL3 was significantly upregulated in HCC and correlated with shorter overall survival of HCC patients [119]. Kaplan-Meier survival curve analysis showed that high METTL3 expression was associated with poor survival (including disease related survival (DSS)). survival (DSS), overall survival (OS), progression-free survival (PFS) and disease free interval (DFI), and recurrence-free survival (RFS) were poorly correlated, which is a prognostic independent predictor of hepatocellular carcinoma [120, 121]. METTL3-mediated methylation of Hsa_circ_0058493 m6A accelerates hepatocellular carcinoma progression and induces poorer prognosis through binding to YTHDC 1 [122]. Meanwhile, METTL3 upregulation in HCC marks Lenvatinib resistance and is a biomarker for predicting the efficacy of Lenvatinib in HCC [123]. The high expression of METTL3 in ICC mainly upregulates the m6A modification of NFAT5 mRNA, which recruits IGF2BP1 for the stabilization of NFAT5 mRNA. Elevated NFAT5 expression increases the expression of gluconeogenesis-related genes GLUT1 and PGK1, leading to enhanced aerobic glycolysis, proliferation and tumor metastasis in ICC.METTL3 is a poor prognostic factor for ICC patients [124]. In colorectal cancer (CRC), high expression of METTL3 promotes the proliferation, migration, and invasive process of CRC cells. Epitope transcriptomics microarrays revealed that the cell polarity regulator Crumbs 3 (CRB3) is a downstream target of METTL3. Knockdown of the METTL3 gene resulted in a significant decrease in CRB3 m6A levels, inhibition of CRB3 mRNA degradation, and increased CRB3 expression. METTL3 promotes colorectal cancer progression by regulating the m6 A-CRB3- Hippo axis, and CRC patients with high m6A or METTL3 levels have shorter overall survival. Meanwhile, METTL3 promotes CRC growth and metastasis through m6A modification of the coding sequence region of the YPEL5 transcript, which exerts epigenetic repression of YPEL5 [125]. Meanwhile, METTL3 plays an important role in promoting CRC angiogenesis through the METTL3/LINC 00662/VEGFA axis. The specific mechanism is that LINC 00662 and VEGFA RNAs have METTL3-rich sites. METTL3 can dually regulate the stability of LINC 00662 and VEGFA RNAs to maintain their expression and promote angiogenesis in CRC, which in turn facilitates CRC progression. The effect of METTL3 inhibitors on CRC angiogenesis has not yet been investigated, thus this is a promising direction [126]. METTL3 is considered a poor prognostic factor in CRC patients [127]. Interestingly, METTL3 exhibited its cancer suppressive effects in CRC by regulating the p38/ERK pathway, which suggests us that METTL3 plays a rather complex role in the regulation of colorectal cancer [128]. METTL3 is significantly upregulated in bladder cancer (BCa) and promotes Bca cell proliferation, migration, and invasion. METTL3 can be associated with RAS-related (RRAS) mRNA m6A sites and inhibit the transcriptional activity of RRAS. Meanwhile, YTHDF 2 recognizes the m6A site of RRAS and mediates the degradation of RRAS, promoting tumor growth and metastasis. Targeting the METTL3/RRAS/YTHDF 2 regulatory axis may prove to be a promising strategy for the diagnosis and treatment of BCa. However, the specific mechanisms underlying the rise in METTL3 levels in BCa and the correlation between METTL3 expression and patient prognosis remain to be explored [129]. Up-regulation of METTL3 expression in oral squamous cell carcinoma (OSCC) promotes OSCC cell proliferation, self-renewal, migration, and invasive processes, mainly through BMI1 m6 A methylation at the post-transcriptional level to facilitate the translation of BMI1 in OSCC. The METTL3-m6 A-BMI1 axis may serve as a prognostic biomarker or a therapeutic target for OSCC patients [130]. Meanwhile, METTL3 also regulates the m6A modification process of PRMT 5 and promotes PRMT 5 expression, which in turn promotes metastasis and proliferation of OSCC. However, the specific mechanisms and signaling pathways remain to be explored [90]. METTL3 is upregulated in prostate cancer (PCa) tissues and promotes MYC expression through m6A modification, which promotes PCa cell growth and progression [131]. METTL3 upregulation is more pronounced in Pca tissues with bone metastasis, which can increase the ITGB1 expression level to promote the recruitment of PCa cells to collagen I through m6A modification, thus enhancing cell motility and bone metastasis [132]. METTL3 is a poor prognostic factor for overall and disease-free survival in PCa.METTL3 can also enhance MYC (c-myc) expression to promote PCa cell proliferation, invasion, and migration by increasing the level of m6 A of MYC mRNA transcripts, which is a poor prognostic factor for overall and disease-free survival in patients with PCa [131]. Compared with paracancerous tissues, METTL3 expression was higher in cervical cancer tissues; METTL3 overexpression was closely associated with higher FIGO stage as well as poorer pelvic lymph node metastasis, 5-year recurrence-free survival, distant-metastasis-free survival, progression-free survival, and overall survival, and was an independent indicator of poor prognosis for patients with early-stage cervical cancer [133]. In vitro and in vivo, METTL3 overexpression significantly promotes the metastasis of cervical cancer cells. The specific mechanism was that METTL3 mediated the m6A modification of the untranslated region at the 5′ end of histone Tissue L (CTSL) mRNA, and in turn, the m6A reading protein Insulin-like Growth Factor 2 (IGF2BP2) binds to the m6A site, which enhances the stability of the CTSL mRNA, thus promoting the metastasis of cervical cancer cells. Highly expressed METTL3 is closely associated with poor prognosis in cervical cancer [134]. METTL3 is highly expressed in gastric cancer, promotes proliferation and migration of gastric cancer cells and correlates with poor prognosis of patients. METTL3 mediates the m6A modification of DEK mRNA, which binds to the DEK 3’UTR through m6A, resulting in an increase in the stability of DEK mRNA and promoting DEK expression, promoting gastric cancer cell growth and metastasis [135]. METTL3 is also an independent predictor of poor prognosis in esophageal and nasopharyngeal cancers [136–138], and is highly expressed and predictive of poor prognostic outcomes in cancers such as glioblastoma and uroepithelial carcinoma of the bladder [110, 139, 140].METTL3 is highly expressed and predictive of poor prognostic outcomes in Kidney renal clear cell carcinoma (KIRC) tissues, and METTL3 expression is significantly upregulated in Kidney renal clear cell carcinoma (KIRC) tissues. METTL3 regulates HHLA 2 expression mainly through m6A modification of HHLA 2 mRNA, and the METTL3/HHLA 2 axis promotes tumorigenesis in KIRC. Compared with patients with high METTL3 expression, patients with low METTL3 expression had better OS [141]. However, compared to paraneoplastic tissues, renal cell carcinoma (RCC) tissues had lower METTL3 expression, which inhibited cell proliferation, migration, and invasion. Moreover, METTL3 inhibits tumor growth by promoting cell cycle G0/G1 arrest. Higher expression of METTL3 may predict better survival outcomes in RCC patients [142]. METTL3 is usually considered to represent a diagnosed malignant phenotype with a poor prognosis, but the finding that METTL3 can act as a prognostic factor in RCC suggests that METTL3 has complexity in serving as a cancer biomarker.

The role of METTL7A as a biomarker in cancer diagnosis

METTL7A expression is downregulated in lung adenocarcinoma (LUAD) and plays an important role in the diagnosis and prognosis of LUAD. In addition, METTL7A was significantly associated with the clinical phenotype of LUAD patients. In most cancers, METTL7A was associated with favorable Overall Survival. While in BRCA and LAML, METTL7A was identified as a high-risk factor. There was age variability as well as stage variability in METTL7A expression, with patients younger than 60 years of age exhibiting higher METTL7A expression in STAD, BRCA, and UCEC, while patients in the same cohort had lower METTL7A expression in LUAD than patients older than 60 years of age; METTL7A expression was higher in early stage (I/II) tumors than in advanced stage (III/IV) tumors. The above studies suggest that METTL7A is a potential early biomarker for LUAD diagnosis and follow-up [94]. METTL7A is closely related to methylation and lipid metabolism and can be involved in a variety of tumorigenesis and development. In renal clear cell carcinoma (KIRC), mesothelioma and sarcoma, low expression of METTL7 A was significantly associated with poor worst overall survival (OS), disease-specific survival (DSS) and progression-free interval (PFI). Among them, the potential of METTL7A as a diagnostic prognostic biomarker in KIRC is high, but the specific mechanism of METTL7A biomarker in cancer needs to be validated by further experiments [84].

The role of METTL7B as a biomarker in cancer diagnosis

METTL7B is predominantly secreted intracellularly in lung adenocarcinoma (LUAD) tissues with significantly high expression, which can promote LUAD cell proliferation, migration, invasion, and cell cycle regulatory processes. High expression of METTL7B is closely associated with short survival of LUAD patients. According to the Kaplan-Meier plotter database, LUAD patients with low METTL7B expression have relatively good overall survival (OS) and disease-specific survival (DSS). Meanwhile, since METTL7B is also secreted in the extracellular region, it was demonstrated that METTL7B could be clinically applied as a serum diagnostic biomarker by comparing the METTL7B levels in clinical sera of tumor patients with those of healthy volunteers [95, 143]. mRNA and protein of METTL7B are both up-regulated in NSCLC and are involved in CCND1-associated cell cycle regulation. Elevated expression of METTL7B is associated with poor prognosis in NSCLC patients [144]. METTL7B is positively correlated with OS and DFS in patients with low-grade glioma (LGG) and immune cell infiltration of LGG; and participates in extracellular matrix (ECM) and immune-related pathways in LGG, contributing to cell proliferation, cancer progression and EMT. Therefore, METTL7B is a LGG prognostic marker [145].

The role of METTL13 as a biomarker in cancer diagnosis

Tumor cells have a high rate of protein synthesis, and therefore dysregulation of translation mechanisms is common, making it a common cause of tumor-related diseases [146, 147]. Among them, translation elongation regulators such as METTL13 play an important role in the regulation of protein synthesis [148, 149]. METTL13 expression is higher in head and neck squamous carcinoma (HNSCC) than in paracancerous tissues, and in vitro and in vivo experiments have demonstrated that METTL13 enhances the translational efficiency of Snail, which plays an important role in EMT. The elevated level of METTL13 and the prognosis of cancer patients showed a negative correlation and was a prognostic marker for overall survival in HNSCC patients [126]. However, METTL13 is an oncogene of KIRC and can inhibit KIRC growth and metastasis. Knockdown and overexpression of METTL13 resulted in increased and decreased proliferation, viability, invasive migration ability, and epithelial-mesenchymal transition (EMT) of KIRC cells, respectively, and the specific mechanism was then that METTL13 down-regulated the PI 3 K/ AKT/mTOR/HIF-1α pathway and bound to c-Myc to inhibit c-Myc protein expression. Compared with paracancerous tissues, METTL13 is under-expressed in KIRC, and its low expression is closely associated with poor prognosis of KIRC, which is a potential diagnostic marker and therapeutic target for KIRC, and plays a role in the diagnosis of pathological features of KIRC and the prediction of patient prognosis [150].

The role of METTL14 as a biomarker in cancer diagnosis

The expression level of METTL14 in renal cell carcinoma (RCC) is lower than that in normal tissues, and down-regulation of METTL14 expression predicts poor prognosis of renal cell carcinoma. METTL14 inhibits RCC cells by up-regulating the m6A level of NEAT1_1, which in turn down-regulates the expression of NEAT1_1 through the selective recognition of m6A markers on NEAT1_1 via YTHDF2 [151]. METTL14 was significantly downregulated in KIRC tissues. In vitro experiments verified that METTL14 inhibited the proliferation and migration of KIRC cells, while overexpression of METTL14 increased the enrichment of m6A on chromosome 10 Pten, increased Pten mRNA stability in a YTHDF 1-dependent manner, and acted as an anti-tumor effect, which is a good prognostic marker for KIRC [94]. The expression of METTL14 was decreased in acute myeloid leukemia (AML), which affects m6A modification and thus promotes AML development, proving that METTL14 is a prognostic biomarker for AML [152]. Downregulation of METTL14 expression correlates with advanced clinicopathological features and poor prognosis of oral squamous cell carcinoma (OSCC). The level of METTL14 expression is closely correlated with the T-stage and degree of differentiation of OSCC. In vivo and in vitro experiments demonstrated that METTL14 down-regulation promotes OSCC growth and cervical lymph node metastasis, and the specific mechanism is that METTL14 inhibits the autophagy-related gene RB 1CC 1 expression through m6 A-IGF 2BP 2-dependent manner, which exerts an inhibitory effect on OSCC. This suggests that METTL14 is closely related to the prognosis of OSCC patients and is a favorable survival factor for OSCC patients [153]. Both univariate and multifactorial Cox regression analyses showed that METTL14 was an independent favorable factor affecting the prognosis of colorectal cancer [154]. METTL14 expression was down-regulated in CRC, which could inhibit the malignant process of CRC and suppress the process of proliferation invasion and migration of CRC cells through SOX 4-mediated EMT process and PI3K/AKT signaling. stearoyl-CoA desaturase 1 (SCD1) is also a downstream target gene of METTL14-mediated m6 A modification, which can reduce the level of SCD1 mRNA through m6A modification of SCD1 mRNA in a YTHDF 2-dependent manner, and then inhibit the tumorigenic process of CRC through the SCD1-mediated Wnt/β-catenin signaling pathway [155]. Significant downregulation of METTL14 in gastric adenocarcinoma (STAD) predicted TNM stage in STAD as well as poorer overall survival. METTL14 inhibits PTEN expression through an m6 A modification-dependent mechanism, which in turn inhibits STAD growth and liver metastasis in vivo. IGF2BP2 and IGF2BP3 are potential binding proteins for PTEN m6A modification sites, prolonging STAD half-life of PTEN mRNA in cells, which was positively correlated with PTEN expression. Therefore, METTL14 is a potential biomarker for STAD prognostic and therapeutic targets, and METTL14 agonists have broad clinical applications in tumor therapy [156]. Meanwhile, METTL14 is down-regulated in cancers such as triple-negative breast cancer (TNBC) [157], esophageal cancer (EC) [158], osteosarcoma (OS) [16], hepatocellular carcinoma [121], and nephroblastoma [159], and its low expression has been associated with poor prognosis in cancer patients.

Most studies have shown that METTL14 can play a role in cancer inhibition, but some studies have also confirmed that METTL14 can promote tumorigenesis and development [160]. The expression of METTL14 is closely related to the survival of pancreatic cancer patients. The specific mechanism is that METTL14 overexpression triggers an increase in the level of p53 m6 A, while decreasing the mRNA and protein levels of PERP, which is associated with poor prognosis of patients.METTL14 is also a poor prognostic factor in breast cancer.METTL14 overexpression can promote tumor invasion and metastasis through the modification of hsa-miR 146 a-5 p by m6A [161]. METTL14 can participate in the LINC 00942-METTL14-CXCR 4/CYP 1B1 pathway to play a pro-BRCA role [162]. The AURKA gene can inhibit the degradation of METTL14 through the ubiquitination pathway, which also plays a pro-carcinogenic role [163]. The up-regulation of METTL14 plays a better diagnostic role in the peripheral blood screening of breast cancer [164]. Meanwhile, METTL14 and WTAP are upregulated in head and neck squamous cell carcinoma (HNSCC), which is instructive for prognostic prediction in HNSCC [95].

The role of other members of the METTL family as a biomarker in cancer diagnosis

The N3-methylcytidine (m3C) gene, METTL2A, is highly expressed in breast invasive carcinoma (BRCA), and differential analysis showed that METTL2A was differentially expressed in cancer and paracancerous tissues more strongly than METTL6 and METTL8. The amplification rate of METTL2A was approximately 7-fold that of METTL6 [165]. Enrichment analysis showed that METTL2A mainly functions in DNA synthesis and cell proliferation pathways. The above analysis suggests that METTL2A is a poor prognostic factor for BRCA patients and is associated with poorer survival outcomes [166]. In HCC tissues and cells, METTL5 expression was increased. high METTL5 expression was associated with poor prognosis in HCC patients. Knockdown of METTL5 can inhibit PD-L1 expression and malignant cell behavior in HCC by suppressing the Myc pathway [167]. METTL6 was highly expressed in HCC tissues compared with adjacent non-tumor tissues, which was closely associated with poorer survival outcomes in HCC patients [168]. METTL11B expression was higher in CRC tissues than in paraneoplastic tissues, and in CRC patients, progression-free survival and overall survival were significantly higher in the low METTL11B-expressing group than in the high METTL11B-expressing group, respectively (both P < 0.05). METTL11B is closely associated with poor patient prognosis and is an independent risk factor affecting CRC prognosis [76]. METTL16 expression is up regulated in HCC, which promotes HCC cell proliferation, migration, and invasion, and its increased expression is associated with poor prognosis of HCC patients [169]. In BLCA patients, METTL16 was downregulated in bladder cancer (BLCA) compared to normal tissue adjacent to the cancer. Low expression of METTL16 was associated with higher TNM stage and poor prognosis in bladder cancer patients [170]. Compared to normal tissues, METTL24 expression was significantly lower in KIRC tissues, which correlated with lower survival in KIRC patients. This suggests that METTL24 is a protective factor in KIRC and can be used as a prognostic indicator for the diagnosis and treatment of KIRC [98]. Finally, we draw supplementary material 1 to summarize.

The role of METTL protein family in cancer treatment

The role of the METTL family of proteins in a variety of cancers has led it to be viewed as a potential target for cancer therapy, playing a facilitating or inhibitory role in cancer chemotherapy, targeted therapy, immunotherapy, and other therapies (Table 2). Currently, drugs such as 5-fluorouracil (5-FU), cisplatin, and gemcitabine have become the standard of care in cancer treatment. However, accordingly, the resistance to these drugs also poses a considerable challenge to cancer treatment. Many studies have demonstrated that the METTL family of proteins plays an indispensable role in the resistance to these drugs. Interestingly, the METTL family of proteins can also regulate the therapeutic efficiency of certain drugs through mRNA epigenetic modifications. In addition, the role of METTL protein family inhibitors in cancer therapy is also emerging in basic clinical research, and the development and study of METTL protein family inhibitors is a new and promising direction. At the same time, existing research suggests that cancer-related healthcare beyond treatment is an issue that should not be ignored and that cancer healthcare accounts for a low proportion of total healthcare expenditure compared to the burden of the disease [171]. As personalized medicine becomes more prevalent in healthcare, the focus on healthcare is increasing [172, 173]. Thus, it is easy to see that cancer treatment and healthcare go hand in hand. As we further deepen our understanding of the mechanisms by which the METTL family of proteins regulates the development of cancer, this will contribute to the healthy development of treatment and healthcare. Currently, METTL1, METTL3, METTL7A, METTL7B, METTL14, and METTL16 have been reported in clinical studies, and the translational process of applying the basic research results of the METTL protein family to the clinic is crucial.

The role of METTL protein family in therapy resistance

The role of METTL1 in therapy resistance

Tumor cell lines with higher METTL1 expression are more sensitive to drugs targeting chromatin histone methylation, ERK-MAPK, and Wnt signaling pathways, whereas relatively lower sensitivity to drugs targeting cell cycle, apoptosis, protein stability, and degradation signaling pathways is associated with resistance to these drugs. Thus, patients with higher METTL1 benefit from drugs targeting chromatin histone methylation, ERK-MAPK, and WNT pathways rather than cell cycle, apoptosis, and protein stability and degradation signaling pathways [88]. Lenvatinib, a tyrosine kinase inhibitor, is used as first-line therapy for advanced HCC. However, the development of resistance to Lenvatinib in HCC limits its efficacy and treatment duration. Lenvatinib-induced m7G tRNA modification enhances EGFR translation, which further triggers resistance [105]. In HeLa cells, knockdown of METTL1 significantly enhanced cell sensitivity to 5-FU chemotherapy [174].

The role of METTL3 in therapy resistance

METTL3 can regulate MALAT1 expression through m6A methylation modification of MALAT1, which in turn recruits E2F1 and activates downstream AGR2 expression to promote resistance to Adriamycin in breast cancer patients [175, 176]. METTL3 also accelerates the expression of pri-microRNA 221–3 through m6A-dependent manner to miR-221–3 p-mature conversion, which in turn negatively regulates the oncogene HIPK 2-mediated degradation of Che-1 and promotes drug resistance to Adriamycin in MCF-7 breast cancer cells [177]. Hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR + HER2-) breast cancer chemotherapy is less efficient. METTL3 depletion was detected in HR + HER2- BC. METTL3 can regulate EMT through cyclin-dependent inhibitor kinase 1 A (CDKN 1 A); and METTL3 depletion can inhibit apoptosis by down-regulating Bax and thus caspase-3/-9/-8 signaling. reduce the efficiency of chemotherapy. Therefore, METTL3 is a potential therapeutic target for reversing chemoresistance in HR + HER2- BC and a good prognostic marker for HR + HER2- [178]. In gastric cancer, METTL3 promotes PARP1 mRNA stability and thus resistance to oxaliplatin in gastric cancer CD 133 + stem cells [179]. Chemoresistance to 5-fluorouracil (5-FU) is a major obstacle to the outcome of colorectal cancer (CRC) patients. Up-regulation of METTL3 expression was observed in 5-FU-resistant CRC cells, and inhibition of METTL3 inhibited glycolysis and restored chemosensitivity in 5-FU-resistant CRC cells. Specifically, METTL3 increased LDHA transcription by stabilizing hypoxia-inducible factor 1 α (HIF-1α) mRNA, and METTL3 also initiated the translation of LDHA mRNA through the recruitment of YTH structural domain family protein 1 (YTHDF 1), etc., and enhanced the expression of LDHA, which catalyzes the conversion of pyruvate to lactate, thereby triggering the glycolysis and 5-FU resistance of CRC cells. 5-FU resistance. Therefore, METTL3/LDHA-induced metabolic reprogramming is a potential therapeutic target for CRC resistance [180, 181]. Exosomes are extracellular vesicles that can regulate a variety of biological processes and can carry proteins, lipids, DNA and RNA. Among them, exosomes carrying miRNAs can be taken up by recipient cells, and exosomal miRNAs have been shown to affect tumor proliferation and metastasis. high expression of METTL3 in CRC promotes the binding of DGCR8 to pri-miR-181d-5p in an m6A-dependent manner, which results in increased expression of exosome-derived miR-181d-5p in cancer-associated fibroblasts (CAFs), and increased expression of miR-181d-5p in CAFs. expression is increased, and miR-181d-5p directly targets neurocalcin δ to inhibit the 5-FU sensitivity of CRC cells [182]. Li et al. used the Cancer Genome Atlas database to analyze and found that METTL3 expression was elevated in both primary and metastatic CRC lesions compared to normal tissues and that the expression of METTL3 was elevated in both CRC lesions when XALIX (OXA + Capecitabine) and FOLFOX (5-FU + OXA) were used as first-line regimens, patients with high METTL3 expression benefited less from chemotherapy [183]. METTL3-mediated upregulation of MALAT 1 through YTHDF 1/3 is associated with metastasis and drug resistance in lung cancer [184]. METTL3 is overexpressed in chemotherapy-resistant NSCLC tissues and is involved in NSCLC progression and chemoresistance by activating AKT1 protein through regulating the m6A level of AKT1 mRNA. Therefore, the METTL3-AKT1 axis is an effective therapeutic target for chemoresistance in NSCLC [185]. There is a strong association between betel nut and oral cancer. Betel nut chewers are much more likely to develop oral cancer than those who do not chew betel nut, and oral cancer patients who regularly consume betel nut have significantly lower five-year survival rates. As a result, the International Agency for Research on Cancer and the World Health Organization have classified betel nut/ betel nut as a Group 1 human carcinogen. Betel nut alkaloid betel nut, the most common alkaloid in betel nut extracts, is considered to be the major active carcinogen contributing to the pathogenesis and progression of oral cancer [186], which drives the pathologic progression of oral squamous cell carcinoma (OSCC). Arecoline-activated OSCC cell lines and oral squamous carcinoma tissues of betel nut chewers showed a significant up-regulation of METTL3, which induced a significant increase in OSCC through the METTL3/HIF-1α/MYC signaling pathway induced cisplatin resistance in OSCC [187]. Lenvatinib is a tyrosine kinase inhibitor (TKI), but its therapeutic efficacy is limited by drug resistance. In lenvatinib-resistant HCC cells, METTL3 undergoes significant up-regulation, which can regulate EGFR mRNA translation in an m6A-dependent manner, driving lenvatinib resistance in HCC through the METTL3-m6 A-EGFR axis [188]. m6A-mediated METTL3-ATP-mediated RHPN1-RAHAS1 modification accelerates cisplatin resistance in OC by activating the PI3K/AKT pathway to promote the proliferative invasive migratory process in ovarian cancer (OC) [189]. In addition, METTL3 may promote drug resistance in pancreatic cancer [110, 190].

The role of METTL7A in therapy resistance

Multiple myeloma (MM) is a malignant tumor in which plasma cells accumulate in the bone marrow [191], and the main therapeutic agents are the proteasome inhibitors Bortezomib or Carfilzomib, but MM is susceptible to resistance to these agents, which affects the therapeutic efficacy of treatment [192]. Bone marrow adipocytes have been shown to promote MM cell growth and lead to MM resistance by inhibiting chemotherapy-induced apoptosis of tumor cells [193]. The specific mechanism is that METTL7A mediates the m6A methylation of L0 C606724 and SNHG 1 isochronous non-coding RNA (LncRNA), which contributes to the interaction of LncRNA with RNA-binding proteins, which in turn promotes the enrichment of LncRNAs in adipocyte exosomes and mediates MM drug resistance. Meanwhile, MM cells can elevate the methylation level of METTL7A protein via EZH2, which promotes the packaging of LncRNA into adipocyte exosomes and further promotes MM resistance [194]. METTL7A also promotes MM methotrexate resistance through activation of the pro-survival signaling pathway and attenuation of reactive oxygen species accumulation in choriocarcinoma cells [84].

The role of METTL14 in therapy resistance

METTL14 shows low expression in CRC tissues and plays a role in CRC drug resistance. The specific mechanism is that downregulation of METTL14 leads to a decrease in m6A levels, inhibition of recognition and binding of pri-miR-17 by YTHDC2, which in turn promotes the stability of pri-miR-17 mRNA, increases the expression of pri-miR-17 and miR-17-5p, and inhibition of MFN 2 by overexpressed miR-17-5p, resulting in decreased mitochondrial fusion, decreased mitochondrial fission and enhanced mitochondrial autophagy, ultimately inducing reduced 5-FU sensitivity. The METTL14/miR-17- 5 p/MFN2 signaling axis plays a key role in inducing CRC 5-FU chemoresistance [195]. Oxidative stress induced by chemotherapeutic agents promotes m6A methylation modification of PHLDB2 by METTL14, upregulates PHLDB2 protein expression, and upregulated PHLDB 2 reduces the binding affinity between EGFR and the EGFR recycling protein Rab11A, stabilizes the epidermal growth factor receptor (EGFR), facilitates its nuclear translocation and inhibits inhibition of ubiquitin-mediated EGFR degradation, leading to activation of EGFR signaling and subsequent Cetuximab resistance in CRC [196].

Currently, cisplatin treatment is the standard of care for NSCLC, but cisplatin resistance is widely seen in NSCLC, greatly reducing treatment efficacy and patient survival [197]. METTL14 is highly expressed in NSCLC and is increased to a greater extent in cisplatin-resistant cells.METTL14 can be recognized by up-regulating the level of p53 m6A, recognizing DGCR8 and through DGCR8, it can be used for the expression of pri-miR-19 [198]. METTL14 can recognize DGCR8 by upregulating p53 m6A level, recognize DGCR8 and through DGCR8, recognize and process pri-miR-19a, promote the conversion of pri-miR-19a to miR-19a-5p and upregulate the latter, and target RBM24 with miR-19a-5p and downregulate its expression, thus reducing RBM 24 binding to AXIN 1 and inhibiting AXIN 1 transcription, and enhancing cisplatin resistance in NSCLC. Since AXIN1 is a core component of the Wnt pathway, overexpression can down-regulate the malignant phenotype of NSCLC and enhance NSCLC apoptosis [198], and silencing of AXIN1 induces NSCLC metastasis by accelerating the epithelial-mesenchymal transition process [199]. Therefore the effect of METTL14 on the Wnt pathway in NSCLC is a direction worth mining [200]. In pancreatic cancer, knockdown of METTL14 enhances the sensitivity of cancer cells to cisplatin and promotes apoptosis and autophagy by inhibiting AMPKα, ERK 1/2 and mTOR signaling pathways [201]. Similarly, inhibition of METTL14 also enhanced gemcitabine sensitivity of PC cells by downregulating CDA [202].

Table 2 The METTL protein family in tumor drug resistance

Member	Cancer type	Medicine	Effect	Reference	
METTL1	Pan cancer	Drugs targeting cell cycle, apoptosis, protein stability and degradation signaling pathways	Reduces drug sensitivity, induces drug resistance	[88]	
Hepatocellular carcinoma	Lenvatinib	Enhances EGFR translation, triggers drug resistance	[105]	
Cervical cancer	5-FU	Decreases chemosensitivity	[174]	
METTL3	Breast cancer	Adriamycin	Regulates MALAT1 expression, recruits E2F1 and activates downstream AGR2 expression	[175]	
Accelerates the conversion of pri-microRNA 221–3 to miR-221–3 p maturation in an m6A-dependent manner and negatively regulates oncogene HIPK 2-mediated degradation of Che-1	[177]	
Gastric cancer	Oxaliplatin	Promotes PARP1 mRNA stability and thus promotes the resistance to oxaliplatin in gastric cancer CD 133 + stem cells	[179]	
Colorectal cancer	5-FU	Stabilizes HIF-1α mRNA by m6A modification to increase LDHA transcription; recruits YTHDF 1, which initiates translation of LDHA mRNA and promotes LDHA-catalyzed conversion of pyruvate to lactate, triggering CRC glycolysis and 5-FU resistance.	[180]	
Promotes DGCR8 binding to pri-miR-181d-5p in an m6A-dependent manner, results in an expansion of miR-181d-5p expression, and miR-181d-5p directly targets neurocalcin δ to inhibit 5-FU sensitivity in CRC cells	[182]	
XALIX（OXA + Capecitabine）and FOLFOX (5-FU + OXA)	Patients have less benefit from chemotherapy	[183]	
Oral squamous cell carcinoma	Cisplatin	Induces cisplatin resistance in OSSCC via the METTL3/HIF-1α/MYC signaling pathway	[187]	
Hepatocellular carcinoma	Lenvatinib	Regulates EGFR mRNA translation in an m6A-dependent manner and drives lenvatinib resistance in HCC through the METTL3-m6 A-EGFR axis	[188]	
Ovarian cancer	Cisplatin	Modifies RHPN1-RAHAS1 then activates the PI3K/AKT pathway	[189]	
METTL7A	Multiple myeloma	Bortezomib/Carfilzomib	Mediates m6A methylation of LncRNA and promotes LncRNA enrichment in adipocyte exosomes	[194]	
Elevates METTL7A protein methylation levels via EZH2 promote LncRNA packaging into adipocyte exosomes	
Pan cancer	Methotrexate	Activates pro-survival signaling pathways and attenuates reactive oxygen species accumulation in choriocarcinoma cells	[84]	
METTL14	Colorectal cancer	5-FU	Down-regulation of METTL14 leads to a decrease in m6A levels, inhibits the recognition and binding of pri-miR-17 by YTHDC 2, which in turn promotes the stabilization of pri-miR-17 mRNA, increases the expression of pri-miR-17 and miR-17-5p, and overexpression of miR-17-5p inhibits MFN 2, leading to a decrease in mitochondrial fusion, an enhancement of mitochondrial fragmentation and mitochondrial autophagy, and ultimately induces a decrease in 5-FU sensitivity	[195]	
Cetuximab	Oxidative stress promotes m6A methylation modification of PHLDB2 by METTL14, upregulates PHLDB2 protein expression, reduces the binding affinity between EGFR and Rab11A, stabilizes EGFR, promotes its nuclear translocation and inhibits inhibition of ubiquitin-mediated EGFR degradation, and activates EGFR signaling and cetuximab resistance	[196]	
Non-small cell lung cancers	Cisplatin	Up-regulates the m6A level of p53, recognizes DGCR8 and recognizes and processes pri-miR-19a via DGCR8, promotes the conversion of pri-miR-19a to miR-19a-5p and up-regulates the latter, down-regulates RBM24, reduces the binding of RBM24 to AXIN 1, inhibits AXIN 1 transcription, and enhances NSCLC cisplatin resistance	[197]	

Role of METTL protein family in modulation of therapy efficiency

The METTL protein family plays an important role in regulating the efficiency of cancer therapy by modulating mRNA and tRNA post-transcriptional modification processes. Differential expression of METTL1 has been shown to modulate the therapeutic efficacy of antitumor drugs. METTL1 overexpression enhances the cytotoxicity of cisplatin on cisplatin-resistant CRC cells via mir-149-3p action via the S100 A4/p53 signaling pathway to increase cytotoxic effects [203]. It can also increase the sensitivity of antitumor drugs such as cisplatin and 5-fluorouracil in Hela cells, CRC cells [174, 203]. METTL1 expression is lower in cisplatin-resistant (CR-CC) cells compared to cisplatin-sensitive CC (CS-CC) cells, and overexpression of METTL1 increases chemosensitivity to cisplatin in CRC cells by regulating the miR149-3p/S100A4/p53 axis. However, the specific mechanism of METTL1’s action with miR-149-3 p remains to be further explored [126]. Drug sensitivity analysis showed that Trifluridine, PD 407,824 and Taselisib are effective drugs for the treatment of METTL2A-positive BRCA patients [166]. METTL3 can increase the sensitivity of gastric cancer to mTOR inhibitors by promoting the maturation of the miR-17-92 cluster [204]. Allocryptopine is an isoquinoline alkaloid derived from Macleaya cordata that can be used in oral squamous cell carcinoma (OSCC) therapy. Allocryptopine down-regulates METTL3 expression in a dose-dependent manner and inhibits the m6A modification process of PTCH1, which in turn inhibits the proliferation and epithelial-mesenchymal transition of OSCC cells through the m6A modification-mediated Hedgehog signaling pathway, and attenuates the oncogenic behavior of OSCC [205]. Encapsulation of Cromolyn in chitosan nanoparticles (CSNPs) could lead to further enhancement of the former’s therapeutic effect and bioavailability. Cromolyn CSNP can significantly downregulate METTL3 expression and inhibit the m6A process in MCF-7 cells, which suggests that Cromolyn CSNP is a novel epigenetic anticancer drug [206]. p53 inactivation directly promotes the development of HCC and chemotherapy resistance, so p53 reactivation through epigenetic modification is a promising HCC therapeutic research direction. Studies have shown that the combination of vascular endothelial growth factor receptor inhibitors and p53 activators can exert synergistic anti-cancer effects. The combination of RG7112, a p53 activator, and Apatinib, a vascular endothelial growth factor receptor inhibitor, significantly reduced the binding of METTL3 to p53 mRNA, down-regulated the methylation of p53 m6A, activated p53, and significantly increased the ratio of Bax/Bcl-2 to induce apoptosis in HCC cells, thus exerting anti-HCC effects. However, the mechanism of interaction between METTL3 and p53 has not been fully elucidated, and the METTL3-m6A-p53 axis is a potential target for HCC treatment, and the co-administration of RG7112 and Apatinib is an HCC therapy that takes into account the safety and efficacy of HCC [119]. Metformin attenuates multiple myeloma (MM) cell proliferation and promotes apoptosis by inhibiting METTL3-mediated m6A modification of THRAP3, RBM25, and USP4, as well as their protein expression levels [207]. METTL3 promotes homologous recombinational repair and modulates the response to chemotherapy in breast cancer by upregulating the EGF/RAD51 axis through m6A modification. Knockdown of METTL3 increases the sensitivity of BC cells to adriamycin, promotes the accumulation of DNA damage in BC cells, and induces BC cell death [123]. Carbon-ion radiotherapy is a radical non-surgical treatment with a high rate of localized control and no serious adverse effects, which mainly triggers difficult-to-repair DNA double-strand breaks, inducing cell death and inactivation such as apoptosis, necrosis, autophagy, premature senescence, accelerated differentiation, delayed reproductive death of progeny cells and bystander cell death. In NSCLC, after Carbon-ion radiotherapy, METTL3 and its mediated m6A modification levels were up-regulated, inhibiting the degradation and enhancing the expression of H2AX mRNA, promoting DNA damage repair, and thus promoting the process of proliferation, invasion, and migration of NSCLC cells and counteracting Carbon-ion radiotherapy [208]. Drug sensitivity analysis showed that METTL7A was negatively correlated with LRRK2 inhibitors, histone deacetylase inhibitors, PI4KIII β inhibitors, and BET inhibitors, suggesting that METTL7A may be a good predictor of drug efficacy. However, its specific mechanism still needs to be further investigated [94]. The antitumor effect of METTL13 on ccRCC can be used in renal cancer treatment. On the one hand, it is feasible to use METTL13 agonists. On the other hand, the application of the inhibitory effect of METTL13 on HIF-1α, c-Myc, and metabolism-related genes provides a new strategy for ccRCC treatment [150]. METTL16 co-localized with the prostate transmembrane protein androgen induced-1 (PMEPA 1) with the BLCA cells by binding to the m6 A site of the 3 ‘-UTR of PMEPA1, decreasing its mRNA stability as well as protein expression, thereby increasing cisplatin sensitivity and inhibiting the proliferation of bladder cancer cells through the PMEPA 1-mediated autophagy pathway. And under hypoxic conditions hypoxia-inducible factor 2α (HIF-2α) exerts a pro-tumorigenic effect by binding to the METTL16 promoter region and inhibiting its transcription. Therefore, METTL16 and its upstream and downstream play an important role in improving the therapeutic efficiency of BLCA [170].

The inhibitors of the METTL protein family

The METTL family of proteins has received much attention for its complex regulatory network in cancer development and metastasis. It is up- and down-regulated in a wide range of cancers and exerts pro- or anti-tumorigenic effects. Cancer therapeutic regimens such as targeted therapies and immunotherapies have been developed for the METTL family, which have been shown to play a positive role in the treatment of a variety of cancers. Currently, the development of METTL protein family inhibitors has received extensive attention. However, the development of METTL inhibitors has been mainly focused on METTL3, and therefore not enough research has been conducted on other members of the family. At the same time, the research on METTL inhibitors mainly focuses on the synthesis and screening of the inhibitors, while the exploration of the specific mechanism by which the inhibitors target the METTL family to participate in cellular signaling is not much, which is also a direction that future researchers need to work on (Supplementary material 2).

Early reported METTL3 inhibitors are SAM analogs, such as cmpd2, sinefungin, and cpd-564 [132, 209]. The mechanism of inhibition of SAM analogs-associated METTL inhibitors is mainly through competitive inhibition by structural overlap of METTL3 in complex with the inhibitor, SAM and SAH. However, SAM analogs have the disadvantages of poor cell permeability and low selectivity for other methyltransferases. Therefore, researchers have worked on finding and synthesizing non-SAM analogs of METTL3 inhibitors [210].

STM2457, a potent non-SAM analog METTL3 inhibitor, is also the first RNA methyltransferase modulator to exhibit antitumor activity and therapeutic efficacy in vivo. STM2457 plays a role in the treatment of myelogenous leukemia by specifically targeting a key stem cell subset of AML, and by pharmacological inhibition of METTL3 resulted in AML mouse models of impaired implantation and prolonged survival in AML mouse models [4]; and also synergistically inhibits METTL3 activity with gemcitabine, all of which suggest that reprogramming RNA epigenetic modifications may be a potential therapeutic strategy [124, 211]. Moreover, STM2457 is expected to be used in the treatment of NSCLC. STM2457 upregulates PD-L1 both in vivo and in vitro, which may improve the immunotherapy outcome based on PD-L1 upregulation in NSCLC treatment. Combination of STM2457 and anti-PD-1/PD-L1 treatment to improve the immunotherapy benefit is very feasible [212]. In vivo experiments demonstrated that in HCC STM2457 could overcome Lenvatinib resistance by inhibiting EGFR translation in Lenvatinib-resistant HCC (HCC-LR) cells, suggesting that METTL3 is a potential therapeutic target for overcoming Lenvatinib resistance in HCC. The combination of METTL3 inhibitor STM 2457 with Lenvatinib is promising in HCC treatment [188]. In addition, STC-15, a derivative of STM2457, is the first clinical candidate for human oral formulation targeting METTL3 and has entered a phase I clinical trial (NCT 05584111).

Non-SAM analogs such as UZH 2 and UZH 1a have also been reported as METTL3 inhibitors in previous studies. Among them, UZH 1a mainly exerts its inhibitory effect through strong van der Waals forces and the formation of hydrogen bonds with the polar group of METTL3. UZH 2 is a further optimized form of UZH 1a, which also exerts its inhibitory effect through hydrogen bonding.However, none of them have been clinically studied, and their adverse effects and drug safety are unknown [213, 214]. natural products such as quercetin also inhibit METTL3. Quercetin, a flavonol-type compound, is one of the most abundant of our food one of the natural polyphenols, which exerts inhibitory effects by filling SAM pockets. It is the first METTL3 inhibitor derived from a natural product and the most potent METTL3 inhibitor, inhibiting METTL3 activity and thus reducing m6A levels without affecting m5 C/C levels, and inhibiting the proliferation of four different tumor cell lines at micromolar IC50 levels. However, quercetin requires further studies to demonstrate its METTL3 specificity and whether it influences the expression levels of other RNA modifications. In addition, the potential use and in vivo efficacy of quercetin as a METTL3 inhibitor need further investigation. Structural modification and optimization of quercetin is a direction for future METTL3 inhibitor development [215]. Mutagenic inhibitors such as 4-[2-[5-chloro-1-(diphenylmethyl)-2-methyl-1 H-indol-3-yl]-ethoxy] benzoic acid (CDIBA) and eltrombopag reversibly and non-competitively interact with the METTL3/METTL14 complex and can be used as METTL3 inhibitors. competitively interact with the METTL3/METTL14 complex, which can be used as an alternative approach to inhibit METTL3 activity. In addition, Manna et al. identified hesperidin as a potent inhibitor of METTL3 by computerized screening and molecular dynamics simulations [183].

Conclusions and future directions

In summary, METTL proteins are a family of proteins named by their structural features, which can participate in nucleic acid and protein methylation modification, are abnormally expressed in a variety of tumors, and are associated with biological behaviors such as tumor proliferation, cell cycle, invasive migration, apoptosis and autophagy. The effects of different METTL proteins on tumors are characterized by the duality of promotion and inhibition, which may be determined by the different expression or the state of the tumor microenvironment, and the specific mechanisms need to be studied. Therefore, in-depth analysis of the role of METTL proteins in tumor evolution and related mechanisms is an important issue to be resolved in this field, and more basic and clinical studies are needed in the future to further elucidate the specific mechanisms of METTL proteins, which is expected to become a marker for the diagnosis of tumors and prognosis, and may also become a new target for the treatment of cancer pain.

With the increasing research on this family, the emergence of drug-targeted therapies against METTL proteins has provided new opportunities for targeted tumor therapy. However, on the one hand, as METTL family proteins, as important components of multiprotein complexes, are susceptible to multiple acting components and play different roles under different conditions. On the other hand, the structural similarity of family members becomes a challenge for targeted therapy. All these factors will affect its application as molecular markers and drug action targets. In the future, it is necessary to comprehensively and systematically study the role of the METTL protein family in cancer and related signalling pathways, to construct interaction networks and to reveal its specific mechanism of action in cancer, so as to provide new ideas for targeted therapy of cancer. In addition, there is a need to further search for natural bioactive compounds that can replace small molecule inhibitors to reduce the toxic side effects on normal cells. Meanwhile, RNAs targeting METTL family proteins will be used as a new means of targeting cancer treatment in combination with radiotherapy, chemotherapy and other drugs.

Although current research has only revealed a small part of the role of the METTL protein family in tumorigenesis and progression, more and more data are gradually unravelling the mysteries of the METTL proteins. As we gain a more comprehensive understanding of the function of METTL proteins, it will provide new diagnostic and therapeutic strategies for targeted interventions in the future.

Supplementary Information

Supplementary Material 1.

Supplementary Material 2.

Abbreviations

METTL Methyltransferase-like

RP Retinitis pigmentosa

ID Intellectual disability

SAM S-adenosylmethionine

MTD Methyltransferase domain

TME Tumor microenvironment

pMHCs peptide major histocompatibility complexes

APCs antigen-presenting cells

TCR T-cell receptor

ICOS inducible T cell co stimulator

CD40L CD40 ligand

Tregs Regulatory T cells

Th helper T cells

tTregs thymic Tregs

pTreg peripheral Tregs

Teff effector T cells

PD-L1 Programmed death ligand 1

PD-1 programmed death receptor 1

TIL tumor-infiltrating T-cell

ITGβ1 integrin β1

MDSCs myeloid-derived suppressor cells

CRC Colorectal carcinoma

TMB Tumor mutation burden

WDR 4 WD Repeat Domain 4

HCC hepatocellular carcinoma

m7G 7-methylguanosine

AM Ameloblastic fibroma

ESCC Esophageal squamous cell carcinoma

lncRNAs long chain non-coding RNAs

DSS disease related survival

OS overall survival

PFS progression-free survival

DFI disease free interval

RFS recurrence-free survival

CRB3 Crumbs 3

BCa bladder cancer

OSCC oral squamous cell carcinoma

PCa prostate cancer

CTSL Cathepsin L

IGF2BP2 Insulin-like Growth Factor 2

KIRC Kidney renal clear cell carcinoma

RCC renal cell carcinoma

LUAD lung adenocarcinoma

PFI progression-free interval

LGG low-grade glioma

HNSCC head and neck squamous carcinoma

EMT epithelial-mesenchymal transition

AML acute myeloid leukemia

STAD gastric adenocarcinoma

TNBC triple-negative breast cancer

EC esophageal cancer

m3C N3-methylcytidine

BRCA breast invasive carcinoma

5-FU 5-fluorouracil

HIF-1α hypoxia-inducible factor 1α

HIF-2α hypoxia-inducible factor 2α

YTHDF 1 YTH structural domain family protein 1

CAFs cancer-associated fibroblasts

TKI tyrosine kinase inhibitor

OC ovarian cancer

MM Multiple myeloma

EGFR epidermal growth factor receptor

CSNPs chitosan nanoparticles

TEK Tyrosine kinase endothelial

Acknowledgements

Figures 2-5 were drawn by Figdraw (www.figdraw.com). Structures related to METTL inhibitors in Supplementary material 2 were obtained from https://pubchem.ncbi.nlm.nih.gov/.

Authors’ contributions

Huhu Zhang and Fulin Sun: Writing–original draft, Data curation, Conceptualization. Shuyao Jiang: Data curation. Fanghao Yang, Xiaolei Dong and Guoxiang Liu: Conceptualization. Mengjun Wang, Ya Li, Mohan Su, Ziyuan Wen, Chunjuan Yu and Chenkai Fan: Resource. Xiaoxia Li and Zhe Zhang: Draw tables. Lina Yang and Bing Li: Supervision, Funding acquisition, Conceptualization.

Funding

This work was supported by grants from the National Natural Science Foundation of China (No.81803895, 81471546, 81001346 and 81871231), Taishan Scholars Young Experts Program, China Postdoctoral Science Foundation (No.2020M682131 and 2021T140357), Shandong Province Natural Science Foundation (ZR2021YQ57), Youth Innovation and Technology Plan of Shandong Province (2019KJK016), Science and Technology Project of Qingdao (No. 18-6-1-91-nsh) and China Postdoctoral Science Foundation (No.2020M682131, No.2021T140357).

Availability of data and materials

No datasets were generated or analysed during the current study.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Huhu Zhang and Fulin Sun contributed equally to this work.
==== Refs
References

1. Bennett MR Shepherd SA Cronin VA Micklefield J Recent advances in methyltransferase biocatalysis Curr Opin Chem Biol 2017 37 97 106 10.1016/j.cbpa.2017.01.020 28259085
Bennett MR, Shepherd SA, Cronin VA, Micklefield J. Recent advances in methyltransferase biocatalysis. Curr Opin Chem Biol. 2017;37:97–106.28259085
2. Satterwhite ER, Mansfield KD. RNA methyltransferase METTL16: targets and function. Wiley Interdisciplinary Reviews RNA 2022, 13 (2), e1681.
3. Yue J Lu Y Sun Z Guo Y San León D Pasin F Zhao M Methyltransferase-like (METTL) homologues participate in Nicotiana benthamiana antiviral responses Plant Signal Behav 2023 18 1 2214760 10.1080/15592324.2023.2214760 37210738
Yue J, Lu Y, Sun Z, Guo Y, San León D, Pasin F, Zhao M. Methyltransferase-like (METTL) homologues participate in Nicotiana benthamiana antiviral responses. Plant Signal Behav. 2023;18(1):2214760.37210738
4. Li C Qiao C Ding H Luo Y Clinical significance of methyltransferase-like 16 expression in epithelial ovarian Cancer J Coll Physicians Surgeons–Pakistan: JCPSP 2022 32 12 1576 80 10.29271/jcpsp.2022.12.1576
Li C, Qiao C, Ding H, Luo Y. Clinical significance of methyltransferase-like 16 expression in epithelial ovarian Cancer. J Coll Physicians Surgeons–Pakistan: JCPSP. 2022;32(12):1576–80.
5. Wong JM Eirin-Lopez JM Evolution of Methyltransferase-Like (METTL) proteins in Metazoa: a Complex Gene Family involved in Epitranscriptomic Regulation and other epigenetic processes Mol Biol Evol 2021 38 12 5309 27 10.1093/molbev/msab267 34480573
Wong JM, Eirin-Lopez JM. Evolution of Methyltransferase-Like (METTL) proteins in Metazoa: a Complex Gene Family involved in Epitranscriptomic Regulation and other epigenetic processes. Mol Biol Evol. 2021;38(12):5309–27.34480573
6. Cao J Huang C Liu J Li C Liu X Zheng Z Hou L Huang J Wang L Zhang Y Shangguan X Chen Z Comparative Genomics and Functional studies of putative m(6)a methyltransferase (METTL) genes in cotton Int J Mol Sci 2022 23 22 10.3390/ijms232214111
Cao J, Huang C, Liu J, Li C, Liu X, Zheng Z, Hou L, Huang J, Wang L, Zhang Y, Shangguan X, Chen Z. Comparative Genomics and Functional studies of putative m(6)a methyltransferase (METTL) genes in cotton. Int J Mol Sci. 2022;23:22.
7. Yin L Ma C Hou S Ma X Methyltransferase-like (METTL)14-mediated N6-methyladenosine modification modulates retinal pigment epithelial (RPE) activity by regulating the methylation of microtubule-associated protein (MAP)2 Bioengineered 2022 13 3 4773 85 10.1080/21655979.2022.2032968 35139773
Yin L, Ma C, Hou S, Ma X. Methyltransferase-like (METTL)14-mediated N6-methyladenosine modification modulates retinal pigment epithelial (RPE) activity by regulating the methylation of microtubule-associated protein (MAP)2. Bioengineered. 2022;13(3):4773–85.35139773
8. Almannai M Obaid O Faqeih E Alasmari A Samman MM Pinz H Braddock SR Alkuraya FS Further delineation of METTL23-associated intellectual disability Am J Med Genet: A 2020 182 4 785 91 10.1002/ajmg.a.61503 32067349
Almannai M, Obaid O, Faqeih E, Alasmari A, Samman MM, Pinz H, Braddock SR, Alkuraya FS. Further delineation of METTL23-associated intellectual disability. Am J Med Genet: A. 2020;182(4):785–91.32067349
9. Li M Zhi Z Jiang X Duan GC Zhu WN Pang Z Wang L Ge R Dai X Liu JM Chen TY Jia JJ Li JM Sun L N., METTL9 derived circular RNA circ-METTL9 sponges miR-551b-5p to accelerate colorectal cancer progression by upregulating CDK6 Carcinogenesis 2023 44 6 463 75 10.1093/carcin/bgad031 37158456
Li M, Zhi Z, Jiang X, Duan GC, Zhu WN, Pang Z, Wang L, Ge R, Dai X, Liu JM, Chen TY, Jia JJ, Li JM, Sun L. N., METTL9 derived circular RNA circ-METTL9 sponges miR-551b-5p to accelerate colorectal cancer progression by upregulating CDK6. Carcinogenesis. 2023;44(6):463–75.37158456
10. Ma J Han H Huang Y Yang C Zheng S Cai T Bi J Huang X Liu R Huang L Luo Y Li W Lin S METTL1/WDR4-mediated m(7)G tRNA modifications and m(7)G codon usage promote mRNA translation and lung cancer progression Mol Therapy: J Am Soc Gene Therapy 2021 29 12 3422 35 10.1016/j.ymthe.2021.08.005
Ma J, Han H, Huang Y, Yang C, Zheng S, Cai T, Bi J, Huang X, Liu R, Huang L, Luo Y, Li W, Lin S. METTL1/WDR4-mediated m(7)G tRNA modifications and m(7)G codon usage promote mRNA translation and lung cancer progression. Mol Therapy: J Am Soc Gene Therapy. 2021;29(12):3422–35.
11. Qin Y Li L Luo E Hou J Yan G Wang D Qiao Y Tang C Role of m6A RNA methylation in cardiovascular disease (review) Int J Mol Med 2020 46 6 1958 72 10.3892/ijmm.2020.4746 33125109
Qin Y, Li L, Luo E, Hou J, Yan G, Wang D, Qiao Y, Tang C. Role of m6A RNA methylation in cardiovascular disease (review). Int J Mol Med. 2020;46(6):1958–72.33125109
12. Burgess HM Depledge DP Thompson L Srinivas KP Grande RC Vink EI Abebe JS Blackaby WP Hendrick A Albertella MR Kouzarides T Stapleford KA Wilson AC Mohr I Targeting the m(6)a RNA modification pathway blocks SARS-CoV-2 and HCoV-OC43 replication Genes Dev 2021 35 13–14 1005 19 10.1101/gad.348320.121 34168039
Burgess HM, Depledge DP, Thompson L, Srinivas KP, Grande RC, Vink EI, Abebe JS, Blackaby WP, Hendrick A, Albertella MR, Kouzarides T, Stapleford KA, Wilson AC, Mohr I. Targeting the m(6)a RNA modification pathway blocks SARS-CoV-2 and HCoV-OC43 replication. Genes Dev. 2021;35(13–14):1005–19.34168039
13. Tooley JG Catlin JP Tooley CES METTLing in Stem Cell and Cancer Biology Stem cell Reviews Rep 2023 19 1 76 91 10.1007/s12015-022-10444-7
Tooley JG, Catlin JP, Tooley CES. METTLing in Stem Cell and Cancer Biology. Stem cell Reviews Rep. 2023;19(1):76–91.
14. Ying X Liu B Yuan Z Huang Y Chen C Jiang X Zhang H Qi D Yang S Lin S Luo J Ji W METTL1-m(7) G-EGFR/EFEMP1 axis promotes the bladder cancer development Clin translational Med 2021 11 12 e675 10.1002/ctm2.675
Ying X, Liu B, Yuan Z, Huang Y, Chen C, Jiang X, Zhang H, Qi D, Yang S, Lin S, Luo J, Ji W. METTL1-m(7) G-EGFR/EFEMP1 axis promotes the bladder cancer development. Clin translational Med. 2021;11(12):e675.
15. Bolatkan A Asada K Kaneko S Suvarna K Ikawa N Machino H Komatsu M Shiina S Hamamoto R Downregulation of METTL6 mitigates cell progression, migration, invasion and adhesion in hepatocellular carcinoma by inhibiting cell adhesion molecules Int J Oncol. 2022 60 1 4 10.3892/ijo.2021.5294 34913069
Bolatkan A, Asada K, Kaneko S, Suvarna K, Ikawa N, Machino H, Komatsu M, Shiina S, Hamamoto R. Downregulation of METTL6 mitigates cell progression, migration, invasion and adhesion in hepatocellular carcinoma by inhibiting cell adhesion molecules. Int J Oncol. 2022;60(1):4.34913069
16. Wang T Xu C Zhang Z Wu H Li X Zhang Y Deng N Dang N Tang G Yang X Shi B Li Z Li L Ye K Cellular heterogeneity and transcriptomic profiles during intrahepatic cholangiocarcinoma initiation and progression Hepatology (Baltimore MD) 2022 76 5 1302 17 10.1002/hep.32483 35340039
Wang T, Xu C, Zhang Z, Wu H, Li X, Zhang Y, Deng N, Dang N, Tang G, Yang X, Shi B, Li Z, Li L, Ye K. Cellular heterogeneity and transcriptomic profiles during intrahepatic cholangiocarcinoma initiation and progression. Hepatology (Baltimore MD). 2022;76(5):1302–17.35340039
17. Campeanu IJ Jiang Y Liu L Pilecki M Najor A Cobani E Manning M Zhang XM Yang ZQ Multi-omics integration of methyltransferase-like protein family reveals clinical outcomes and functional signatures in human cancer Sci Rep 2021 11 1 14784 10.1038/s41598-021-94019-5 34285249
Campeanu IJ, Jiang Y, Liu L, Pilecki M, Najor A, Cobani E, Manning M, Zhang XM, Yang ZQ. Multi-omics integration of methyltransferase-like protein family reveals clinical outcomes and functional signatures in human cancer. Sci Rep. 2021;11(1):14784.34285249
18. Zheng JA-O Lu YA-O Lin Y Si S Guo BA-O Zhao XA-O Cui LA-O Epitranscriptomic modifications in mesenchymal stem cell differentiation: advances, mechanistic insights, and beyond Cell Death Differ 2024 31 1 9 27 10.1038/s41418-023-01238-6 37985811
Zheng JA-O, Lu YA-O, Lin Y, Si S, Guo BA-O, Zhao XA-O, Cui LA-O. Epitranscriptomic modifications in mesenchymal stem cell differentiation: advances, mechanistic insights, and beyond. Cell Death Differ. 2024 Jan;31(1):9–27.37985811
19. Breger KA-O Kunkler CA-O O'Leary NA-OX Hulewicz JA-O Brown JA-O Ghost authors revealed: The structure and function of human N(6) -methyladenosine RNA methyltransferases Wiley Interdiscip Rev RNA 2023 6 e1810
Breger KA-O, Kunkler CA-O, O’Leary NA-OX, Hulewicz JA-O, Brown JA-O. Ghost authors revealed: the structure and function of human N(6) -methyladenosine RNA methyltransferases. Wiley Interdiscip Rev RNA. 2023;6:e1810.
20. Vera-Montecinos A, Galiano-Landeira J, Roldán MA-O, Vidal-Domènech F, Claro EA-O, Ramos B. A Novel Localization of METTL7A in Bergmann Glial Cells in Human Cerebellum. Int J Mol Sci. 2023 May 7;24(9):8405.
21. Yang Z, Zhang W, Li L, Hu N, Dong X, Chen Y, Cai W, Yin L, Liu F, Tang D, Dai Y. The novel putative methyltransferase METTL7A as one prognostic biomarker potentially associated with immune infiltration in human renal cancer. Heliyon. 2023 Apr 11;9(4):e15371.
22. Qi YN Liu Z Hong LL Li P Ling ZQ Methyltransferase-like proteins in cancer biology and potential therapeutic targeting J Hematol Oncol 2023 2 1 89 10.1186/s13045-023-01477-7
Qi YN, Liu Z, Hong LL, Li P, Ling ZQ. Methyltransferase-like proteins in cancer biology and potential therapeutic targeting. J Hematol Oncol. 2023;2(1):89.
23. Kostyusheva A Brezgin S Glebe D Kostyushev D Chulanov V Host-cell interactions in HBV infection and pathogenesis: the emerging role of m6A modification Emerg Microbes Infect 2021 10 1 2264 75 10.1080/22221751.2021.2006580 34767497
Kostyusheva A, Brezgin S, Glebe D, Kostyushev D, Chulanov V. Host-cell interactions in HBV infection and pathogenesis: the emerging role of m6A modification. Emerg Microbes Infect. 2021;10(1):2264–75.34767497
24. Zheng J Lu Y Lin Y Si S Guo B Zhao X Cui L Epitranscriptomic modifications in mesenchymal stem cell differentiation: advances, mechanistic insights, and beyond Cell Death Differ 2024 31 1 9 27 10.1038/s41418-023-01238-6 37985811
Zheng J, Lu Y, Lin Y, Si S, Guo B, Zhao X, Cui L. Epitranscriptomic modifications in mesenchymal stem cell differentiation: advances, mechanistic insights, and beyond. Cell Death Differ. 2024;31(1):9–27.37985811
25. Chen M Wei L Law CT Tsang FH Shen J Cheng CL Tsang LH Ho DW Chiu DK Lee JM Wong CC Ng IO Wong C A.-O., RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2 Hepatology 2018 67 6 2254 70 10.1002/hep.29683 29171881
Chen M, Wei L, Law CT, Tsang FH, Shen J, Cheng CL, Tsang LH, Ho DW, Chiu DK, Lee JM, Wong CC, Ng IO, Wong C. A.-O., RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2. Hepatology. 2018 Jun;67(6):2254–70.29171881
26. Peng C Xiong F Pu X Hu Z Yang Y Qiao X Jiang Y Han M Wang D Li X m(6)A methylation modification and immune cell infiltration: implications for targeting the catalytic subunit m(6)A-METTL complex in gastrointestinal cancer immunotherapy Front Immunol 2023 15 1326031 10.3389/fimmu.2023.1326031
Peng C, Xiong F, Pu X, Hu Z, Yang Y, Qiao X, Jiang Y, Han M, Wang D, Li X. M(6)a methylation modification and immune cell infiltration: implications for targeting the catalytic subunit m(6)A-METTL complex in gastrointestinal cancer immunotherapy. Front Immunol. 2023;15:14:1326031.
27. Isono M Nakano M Fukami T Nakajima M Adenosine N(6)-methylation upregulates the expression of human CYP2B6 by altering the chromatin status Biochem Pharmacol 2022 205 115247 10.1016/j.bcp.2022.115247 36113565
Isono M, Nakano M, Fukami T, Nakajima M. Adenosine N(6)-methylation upregulates the expression of human CYP2B6 by altering the chromatin status. Biochem Pharmacol. 2022;205:115247.36113565
28. Li QA-O Yu LA-O Gao A Ren R Zhang J Cao L Wang X Liu Y Qi W Cai L Li W Wang W Guo X Su G Yu XA-O Zhang J Xi BA-O Zhang YA-O Zhang MA-O Zhang C A.-O., METTL3 (Methyltransferase Like 3)-Dependent N6-Methyladenosine Modification on Braf mRNA Promotes Macrophage Inflammatory Response and Atherosclerosis in Mice Arterioscler Thromb Vasc Biol 2023 43 5 755 73 10.1161/ATVBAHA.122.318451 36951060
Li QA-O, Yu LA-O, Gao A, Ren R, Zhang J, Cao L, Wang X, Liu Y, Qi W, Cai L, Li W, Wang W, Guo X, Su G, Yu XA-O, Zhang J, Xi BA-O, Zhang YA-O, Zhang MA-O, Zhang C. A.-O., METTL3 (methyltransferase like 3)-Dependent N6-Methyladenosine modification on Braf mRNA promotes macrophage inflammatory response and atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 2023;43(5):755–73.36951060
29. Song H, Liu D, Wang L, Liu K, Chen C, Wang L, Ren Y, Ju B, Zhong F, Jiang X, Wang G, Chen ZA-OX, Zou C. Methyltransferase like 7B is a potential therapeutic target for reversing EGFR-TKIs resistance in lung adenocarcinoma. Mol Cancer. 2022 Feb 10;21(1):43.
30. Zhang H Dong X Ding X Liu G Yang F Song Q Sun H Chen G Li S Li Y Wang M Guo T Zhang Z Li B Yang L Bufalin targeting CAMKK2 inhibits the occurrence and development of intrahepatic cholangiocarcinoma through Wnt/β-catenin signal pathway J Translational Med 2023 21 1 900 10.1186/s12967-023-04613-6
Zhang H, Dong X, Ding X, Liu G, Yang F, Song Q, Sun H, Chen G, Li S, Li Y, Wang M, Guo T, Zhang Z, Li B, Yang L. Bufalin targeting CAMKK2 inhibits the occurrence and development of intrahepatic cholangiocarcinoma through Wnt/β-catenin signal pathway. J Translational Med. 2023;21(1):900.
31. Zhang H Song Q Shang K Li Y Jiang L Yang L Tspan protein family: focusing on the occurrence, progression, and treatment of cancer Cell Death Discovery 2024 10 1 187 10.1038/s41420-024-01961-0 38649381
Zhang H, Song Q, Shang K, Li Y, Jiang L, Yang L. Tspan protein family: focusing on the occurrence, progression, and treatment of cancer. Cell Death Discovery. 2024;10(1):187.38649381
32. Wang Z Yu P Zou Y Ma J Han H Wei W Yang C Zheng S Guo S Wang J Liu L Lin S METTL1/WDR4-mediated tRNA m(7)G modification and mRNA translation control promote oncogenesis and doxorubicin resistance Oncogene 2023 42 23 1900 12 10.1038/s41388-023-02695-6 37185458
Wang Z, Yu P, Zou Y, Ma J, Han H, Wei W, Yang C, Zheng S, Guo S, Wang J, Liu L, Lin S. METTL1/WDR4-mediated tRNA m(7)G modification and mRNA translation control promote oncogenesis and doxorubicin resistance. Oncogene. 2023;42(23):1900–12.37185458
33. Chen B Jiang W Huang Y Zhang J Yu P Wu L Peng H N(7)-methylguanosine tRNA modification promotes tumorigenesis and chemoresistance through WNT/β-catenin pathway in nasopharyngeal carcinoma Oncogene 2022 41 15 2239 53 10.1038/s41388-022-02250-9 35217794
Chen B, Jiang W, Huang Y, Zhang J, Yu P, Wu L, Peng H. N(7)-methylguanosine tRNA modification promotes tumorigenesis and chemoresistance through WNT/β-catenin pathway in nasopharyngeal carcinoma. Oncogene. 2022;41(15):2239–53.35217794
34. Yuan XN Liu Q Shao YC Guan XQ Yang ZL Chu MF Zhang JW Tian YH Wei L Mettl3 synergistically regulates TGF-β/SMAD2/3 to promote proliferation and metastasis of gastric cancer Am J cancer Res 2023 13 7 3185 202 37560008
Yuan XN, Liu Q, Shao YC, Guan XQ, Yang ZL, Chu MF, Zhang JW, Tian YH, Wei L. Mettl3 synergistically regulates TGF-β/SMAD2/3 to promote proliferation and metastasis of gastric cancer. Am J cancer Res. 2023;13(7):3185–202.37560008
35. Han J Wang JZ Yang X Yu H Zhou R Lu HC Yuan WB Lu JC Zhou ZJ Lu Q Wei JF Yang H METTL3 promote tumor proliferation of bladder cancer by accelerating pri-miR221/222 maturation in m6A-dependent manner Mol Cancer 2019 18 1 110 10.1186/s12943-019-1036-9 31228940
Han J, Wang JZ, Yang X, Yu H, Zhou R, Lu HC, Yuan WB, Lu JC, Zhou ZJ, Lu Q, Wei JF, Yang H. METTL3 promote tumor proliferation of bladder cancer by accelerating pri-miR221/222 maturation in m6A-dependent manner. Mol Cancer. 2019;18(1):110.31228940
36. Hsu KW Lai JC Chang JS Peng PH Huang CH Lee DY Tsai YC Chung CJ Chang H Chang CH Chen JL Pang ST Hao Z Cui XL He C Wu K J., METTL4-mediated nuclear N6-deoxyadenosine methylation promotes metastasis through activating multiple metastasis-inducing targets Genome Biol 2022 23 1 249 10.1186/s13059-022-02819-3 36461076
Hsu KW, Lai JC, Chang JS, Peng PH, Huang CH, Lee DY, Tsai YC, Chung CJ, Chang H, Chang CH, Chen JL, Pang ST, Hao Z, Cui XL, He C, Wu K. J., METTL4-mediated nuclear N6-deoxyadenosine methylation promotes metastasis through activating multiple metastasis-inducing targets. Genome Biol. 2022;23(1):249.36461076
37. Xia P Zhang H Lu H Xu K Jiang X Jiang Y Gongye X Chen Z Liu J Chen X Ma W Zhang Z Yuan Y METTL5 stabilizes c-Myc by facilitating USP5 translation to reprogram glucose metabolism and promote hepatocellular carcinoma progression Cancer Commun (London England) 2023 43 3 338 64 10.1002/cac2.12403
Xia P, Zhang H, Lu H, Xu K, Jiang X, Jiang Y, Gongye X, Chen Z, Liu J, Chen X, Ma W, Zhang Z, Yuan Y. METTL5 stabilizes c-Myc by facilitating USP5 translation to reprogram glucose metabolism and promote hepatocellular carcinoma progression. Cancer Commun (London England). 2023;43(3):338–64.
38. Ignatova VV Kaiser S Ho JSY Bing X Stolz P Tan YX Lee CL Gay FPH Lastres PR Gerlini R Rathkolb B Aguilar-Pimentel A Sanz-Moreno A Klein-Rodewald T Calzada-Wack J Ibragimov E Valenta M Lukauskas S Pavesi A Marschall S Leuchtenberger S Fuchs H Gailus-Durner V de Angelis MH Bultmann S Rando OJ Guccione E Kellner SM Schneider R METTL6 is a tRNA m(3)C methyltransferase that regulates pluripotency and tumor cell growth Sci Adv 2020 6 35 eaaz4551 10.1126/sciadv.aaz4551 32923617
Ignatova VV, Kaiser S, Ho JSY, Bing X, Stolz P, Tan YX, Lee CL, Gay FPH, Lastres PR, Gerlini R, Rathkolb B, Aguilar-Pimentel A, Sanz-Moreno A, Klein-Rodewald T, Calzada-Wack J, Ibragimov E, Valenta M, Lukauskas S, Pavesi A, Marschall S, Leuchtenberger S, Fuchs H, Gailus-Durner V, de Angelis MH, Bultmann S, Rando OJ, Guccione E, Kellner SM, Schneider R. METTL6 is a tRNA m(3)C methyltransferase that regulates pluripotency and tumor cell growth. Sci Adv. 2020;6(35):eaaz4551.32923617
39. Wu Q Hu Q Hai Y Li Y Gao Y METTL13 facilitates cell growth and metastasis in gastric cancer via an eEF1A/HN1L positive feedback circuit J cell Communication Signal 2023 17 1 121 35 10.1007/s12079-022-00687-x
Wu Q, Hu Q, Hai Y, Li Y, Gao Y. METTL13 facilitates cell growth and metastasis in gastric cancer via an eEF1A/HN1L positive feedback circuit. J cell Communication Signal. 2023;17(1):121–35.
40. Li L Zheng YL Jiang C Fang S Zeng TT Zhu YH Li Y Xie D Guan XY HN1L-mediated transcriptional axis AP-2γ/METTL13/TCF3-ZEB1 drives tumor growth and metastasis in hepatocellular carcinoma Cell Death Differ 2019 26 11 2268 83 10.1038/s41418-019-0301-1 30778199
Li L, Zheng YL, Jiang C, Fang S, Zeng TT, Zhu YH, Li Y, Xie D, Guan XY. HN1L-mediated transcriptional axis AP-2γ/METTL13/TCF3-ZEB1 drives tumor growth and metastasis in hepatocellular carcinoma. Cell Death Differ. 2019;26(11):2268–83.30778199
41. Liu X, Xiao M, Zhang L, Li L, Zhu G, Shen E, Lv M, Lu X, Sun Z. The m6A methyltransferase METTL14 inhibits the proliferation, migration, and invasion of gastric cancer by regulating the PI3K/AKT/mTOR signaling pathway. J Clin Lab Anal 2021, 35 (3), e23655.
42. Zhang N Hua X Tu H Li J Zhang Z Max C Isorhapontigenin (ISO) inhibits EMT through FOXO3A/METTL14/VIMENTIN pathway in bladder cancer cells Cancer Lett 2021 520 400 8 10.1016/j.canlet.2021.07.041 34332039
Zhang N, Hua X, Tu H, Li J, Zhang Z, Max C. Isorhapontigenin (ISO) inhibits EMT through FOXO3A/METTL14/VIMENTIN pathway in bladder cancer cells. Cancer Lett. 2021;520:400–8.34332039
43. Yang X Zhang S He C Xue P Zhang L He Z Zang L Feng B Sun J Zheng M METTL14 suppresses proliferation and metastasis of colorectal cancer by down-regulating oncogenic long non-coding RNA XIST Mol Cancer 2020 19 1 46 10.1186/s12943-020-1146-4 32111213
Yang X, Zhang S, He C, Xue P, Zhang L, He Z, Zang L, Feng B, Sun J, Zheng M. METTL14 suppresses proliferation and metastasis of colorectal cancer by down-regulating oncogenic long non-coding RNA XIST. Mol Cancer. 2020;19(1):46.32111213
44. Xie F Zheng Y Fu W Chi B Wang X Zhang J Gu J Yin J Zhou Q Guo S Cai L Yang J Liu S Wang H The m6A methyltransferase METTL16 inhibits the proliferation of pancreatic adenocarcinoma cancer cells via the p21 signaling pathway Front Oncol 2023 13 1138238 10.3389/fonc.2023.1138238 37182151
Xie F, Zheng Y, Fu W, Chi B, Wang X, Zhang J, Gu J, Yin J, Zhou Q, Guo S, Cai L, Yang J, Liu S, Wang H. The m6A methyltransferase METTL16 inhibits the proliferation of pancreatic adenocarcinoma cancer cells via the p21 signaling pathway. Front Oncol. 2023;13:1138238.37182151
45. Yu L Lu J Xie N Fang L Chen S Wu Y Wang X Li B Suppression of Wnt/β-catenin signaling in PDAC via METTL16-mediated N6-methyladenosine modification of DVL2 J Cancer 2023 14 16 2964 77 10.7150/jca.85860 37859814
Yu L, Lu J, Xie N, Fang L, Chen S, Wu Y, Wang X, Li B. Suppression of Wnt/β-catenin signaling in PDAC via METTL16-mediated N6-methyladenosine modification of DVL2. J Cancer. 2023;14(16):2964–77.37859814
46. Sun F, Fang M, Zhang H, Song Q, Li S, Li Y, Jiang S, Yang L. Drp1: Focus on diseases triggered by the mitochondrial pathway. Cell Biochem Biophys 2024.
47. Jiang H Liu Y Song H Xia J Tian Y Wang L Li M Xu Z Xu Z Zou C METTL1 promotes colorectal cancer cell proliferation by attenuating CHEK2-induced G1/S phase arrest Genes Dis 2024 11 2 579 81 10.1016/j.gendis.2023.04.011 37692515
Jiang H, Liu Y, Song H, Xia J, Tian Y, Wang L, Li M, Xu Z, Xu Z, Zou C. METTL1 promotes colorectal cancer cell proliferation by attenuating CHEK2-induced G1/S phase arrest. Genes Dis. 2024;11(2):579–81.37692515
48. Ling Z, Chen L, Zhao J. m6A-dependent up-regulation of DRG1 by METTL3 and ELAVL1 promotes growth, migration, and colony formation in osteosarcoma. Biosci Rep. 2020;40(4):BSR20200282.
49. Liu D, Li W, Zhong F, Yin J, Zhou W, Li S, Sun X, Xu J, Li G, Wen Y, Wang J, Hong M, Cheng Z, Yuan J, Dai L, Sun J, Wang J, Qiu C, Wang G, Zou C. METTL7B is required for Cancer Cell Proliferation and Tumorigenesis in Non-small Cell Lung Cancer. Front Pharmacol. 2020;11:178.
50. Wang XK Zhang YW Wang CM Li B Zhang TZ Zhou WJ Cheng LJ Huo MY Zhang CH He Y L., METTL16 promotes cell proliferation by up-regulating cyclin D1 expression in gastric cancer J Cell Mol Med 2021 25 14 6602 17 10.1111/jcmm.16664 34075693
Wang XK, Zhang YW, Wang CM, Li B, Zhang TZ, Zhou WJ, Cheng LJ, Huo MY, Zhang CH, He Y. L., METTL16 promotes cell proliferation by up-regulating cyclin D1 expression in gastric cancer. J Cell Mol Med. 2021;25(14):6602–17.34075693
51. Li TH Qin C Zhao BB Cao HT Yang XY Wang YY Li ZR Zhou XT Wang WB Identification METTL18 as a potential prognosis Biomarker and Associated with Immune infiltrates in Hepatocellular Carcinoma Front Oncol 2021 11 665192 10.3389/fonc.2021.665192 34123827
Li TH, Qin C, Zhao BB, Cao HT, Yang XY, Wang YY, Li ZR, Zhou XT, Wang WB. Identification METTL18 as a potential prognosis Biomarker and Associated with Immune infiltrates in Hepatocellular Carcinoma. Front Oncol. 2021;11:665192.34123827
52. Zhang H Yang J Song Q Ding X Sun F Yang L UBA3 promotes the occurrence and metastasis of intrahepatic cholangiocarcinoma through MAPK signaling pathway Acta Biochim Biophys Sin 2024 56 2 199 209 10.3724/abbs.2024014 38298057
Zhang H, Yang J, Song Q, Ding X, Sun F, Yang L. UBA3 promotes the occurrence and metastasis of intrahepatic cholangiocarcinoma through MAPK signaling pathway. Acta Biochim Biophys Sin. 2024;56(2):199–209.38298057
53. Ji JW Zhang YD Lai YJ Huang CG Mettl3 regulates the proliferation, migration and invasion of glioma cells by inhibiting PI3K/Akt signaling pathway Eur Rev Med Pharmacol Sci 2020 24 7 3818 28 32329858
Ji JW, Zhang YD, Lai YJ, Huang CG. Mettl3 regulates the proliferation, migration and invasion of glioma cells by inhibiting PI3K/Akt signaling pathway. Eur Rev Med Pharmacol Sci. 2020;24(7):3818–28.32329858
54. Hu S, Song Y, Zhou Y, Jiao Y, Li G. METTL3 Accelerates Breast Cancer Progression via Regulating EZH2 m(6)A Modification. Journal of healthcare engineering 2022, 2022, 5794422.
55. Lee SA Lee KH Kim H Cho JY METTL8 mRNA methyltransferase enhances Cancer Cell Migration via Direct binding to ARID1A Int J Mol Sci 2021 22 11 5432 10.3390/ijms22115432 34063990
Lee SA, Lee KH, Kim H, Cho JY. METTL8 mRNA methyltransferase enhances Cancer Cell Migration via Direct binding to ARID1A. Int J Mol Sci. 2021;22(11):5432.34063990
56. Liu Z, Sun T, Piao C, Zhang Z, Kong C. METTL13 inhibits progression of clear cell renal cell carcinoma with repression on PI3K/AKT/mTOR/HIF-1α pathway and c-Myc expression. J Translational Med. 2021;19(1):209.
57. Wang G, Dai Y, Li K, Cheng M, Xiong G, Wang X, Chen S, Chen Z, Chen J, Xu X, Ling RS, Peng L, Chen D. Deficiency of Mettl3 in bladder Cancer stem cells inhibits bladder Cancer Progression and Angiogenesis. Front cell Dev Biology. 2021;9:627706.
58. Chen J, Li K, Chen J, Wang X, Ling R, Cheng M, Chen Z, Chen F, He Q, Li S, Zhang C, Jiang Y, Chen Q, Wang A, Chen D. Aberrant translation regulated by METTL1/WDR4-mediated tRNA N7-methylguanosine modification drives head and neck squamous cell carcinoma progression. Cancer Commun (London England). 2022;42(3):223–44.
59. Chen C Yuan W Zhou Q Shao B Guo Y Wang W Yang S Guo Y Zhao L Dang Q Yang X Wang G Kang Q Ji Z Liu J Sun Z N6-methyladenosine-induced circ1662 promotes metastasis of colorectal cancer by accelerating YAP1 nuclear localization Theranostics 2021 11 9 4298 315 10.7150/thno.51342 33754062
Chen C, Yuan W, Zhou Q, Shao B, Guo Y, Wang W, Yang S, Guo Y, Zhao L, Dang Q, Yang X, Wang G, Kang Q, Ji Z, Liu J, Sun Z. N6-methyladenosine-induced circ1662 promotes metastasis of colorectal cancer by accelerating YAP1 nuclear localization. Theranostics. 2021;11(9):4298–315.33754062
60. Dai Z Zhu W Hou Y Zhang X Ren X Lei K Liao J Liu H Chen Z Peng S Li S Lin S Kuang M METTL5-mediated 18S rRNA m(6)a modification promotes oncogenic mRNA translation and intrahepatic cholangiocarcinoma progression Mol Therapy: J Am Soc Gene Therapy 2023 31 11 3225 42 10.1016/j.ymthe.2023.09.014
Dai Z, Zhu W, Hou Y, Zhang X, Ren X, Lei K, Liao J, Liu H, Chen Z, Peng S, Li S, Lin S, Kuang M. METTL5-mediated 18S rRNA m(6)a modification promotes oncogenic mRNA translation and intrahepatic cholangiocarcinoma progression. Mol Therapy: J Am Soc Gene Therapy. 2023;31(11):3225–42.
61. Liu J Eckert MA Harada BT Liu SM Lu Z Yu K Tienda SM Chryplewicz A Zhu AC Yang Y Huang JT Chen SM Xu ZG Leng XH Yu XC Cao J Zhang Z Liu J Lengyel E He C M(6)a mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer Nat Cell Biol 2018 20 9 1074 83 10.1038/s41556-018-0174-4 30154548
Liu J, Eckert MA, Harada BT, Liu SM, Lu Z, Yu K, Tienda SM, Chryplewicz A, Zhu AC, Yang Y, Huang JT, Chen SM, Xu ZG, Leng XH, Yu XC, Cao J, Zhang Z, Liu J, Lengyel E, He C. M(6)a mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer. Nat Cell Biol. 2018;20(9):1074–83.30154548
62. Ye F Wu J Zhang F METTL16 epigenetically enhances GPX4 expression via m6A modification to promote breast cancer progression by inhibiting ferroptosis Biochem Biophys Res Commun 2023 638 1 6 10.1016/j.bbrc.2022.10.065 36434904
Ye F, Wu J, Zhang F. METTL16 epigenetically enhances GPX4 expression via m6A modification to promote breast cancer progression by inhibiting ferroptosis. Biochem Biophys Res Commun. 2023;638:1–6.36434904
63. Li H Yu K Hu H Zhang X Zeng S Li J Dong X Deng X Zhang J Zhang Y METTL17 coordinates ferroptosis and tumorigenesis by regulating mitochondrial translation in colorectal cancer Redox Biol 2024 71 103087 10.1016/j.redox.2024.103087 38377789
Li H, Yu K, Hu H, Zhang X, Zeng S, Li J, Dong X, Deng X, Zhang J, Zhang Y. METTL17 coordinates ferroptosis and tumorigenesis by regulating mitochondrial translation in colorectal cancer. Redox Biol. 2024;71:103087.38377789
64. Huang Y Ma J Yang C Wei P Yang M Han H Chen HD Yue T Xiao S Chen X Li Z Tang Y Luo J Lin S Huang L METTL1 promotes neuroblastoma development through m(7)G tRNA modification and selective oncogenic gene translation Biomark Res 2022 10 1 68 10.1186/s40364-022-00414-z 36071474
Huang Y, Ma J, Yang C, Wei P, Yang M, Han H, Chen HD, Yue T, Xiao S, Chen X, Li Z, Tang Y, Luo J, Lin S, Huang L. METTL1 promotes neuroblastoma development through m(7)G tRNA modification and selective oncogenic gene translation. Biomark Res. 2022;10(1):68.36071474
65. Li Y, Li X, Deng M, Ye C, Peng Y, Lu Y. Cancer-Associated Fibroblasts Hinder Lung Squamous Cell Carcinoma Oxidative Stress-Induced Apoptosis via METTL3 Mediated m(6)A Methylation of COL10A1. Oxidative medicine and cellular longevity 2022, 2022, 4320809.
66. Liu X Ma H Ma L Li K Kang Y The potential role of methyltransferase-like 5 in deficient mismatch repair of uterine corpus endometrial carcinoma Bioengineered 2022 13 3 5525 36 10.1080/21655979.2022.2036912 35166644
Liu X, Ma H, Ma L, Li K, Kang Y. The potential role of methyltransferase-like 5 in deficient mismatch repair of uterine corpus endometrial carcinoma. Bioengineered. 2022;13(3):5525–36.35166644
67. Kong F Liu X Zhou Y Hou X He J Li Q Miao X Yang L Downregulation of METTL14 increases apoptosis and autophagy induced by cisplatin in pancreatic cancer cells Int J Biochem Cell Biol 2020 122 105731 10.1016/j.biocel.2020.105731 32097728
Kong F, Liu X, Zhou Y, Hou X, He J, Li Q, Miao X, Yang L. Downregulation of METTL14 increases apoptosis and autophagy induced by cisplatin in pancreatic cancer cells. Int J Biochem Cell Biol. 2020;122:105731.32097728
68. Zhang R Shang L Nan J Niu K Dai J Jin X Zhang X Circ-METTL15 contributes to the proliferation, metastasis, immune escape and restrains apoptosis in lung cancer by regulating miR-1299/PDL1 axis Autoimmunity 2022 55 1 8 20 10.1080/08916934.2021.2001801 34796777
Zhang R, Shang L, Nan J, Niu K, Dai J, Jin X, Zhang X. Circ-METTL15 contributes to the proliferation, metastasis, immune escape and restrains apoptosis in lung cancer by regulating miR-1299/PDL1 axis. Autoimmunity. 2022;55(1):8–20.34796777
69. Li Q Yang L Zhang C Yuan J Zhang J Tao W Zhou J METTL16 deficiency attenuates apoptosis through translational control of extrinsic death receptor during nutrient deprivation Biochem Biophys Res Commun 2024 708 149802 10.1016/j.bbrc.2024.149802 38520913
Li Q, Yang L, Zhang C, Yuan J, Zhang J, Tao W, Zhou J. METTL16 deficiency attenuates apoptosis through translational control of extrinsic death receptor during nutrient deprivation. Biochem Biophys Res Commun. 2024;708:149802.38520913
70. Debnath J Gammoh N Ryan KM Autophagy and autophagy-related pathways in cancer Nat Rev Mol Cell Biol 2023 24 8 560 75 10.1038/s41580-023-00585-z 36864290
Debnath J, Gammoh N, Ryan KM. Autophagy and autophagy-related pathways in cancer. Nat Rev Mol Cell Biol. 2023;24(8):560–75.36864290
71. Sun Y Shen W Hu S Lyu Q Wang Q Wei T Zhu W Zhang J METTL3 promotes chemoresistance in small cell lung cancer by inducing mitophagy J Experimental Clin cancer Research: CR 2023 42 1 65 10.1186/s13046-023-02638-9
Sun Y, Shen W, Hu S, Lyu Q, Wang Q, Wei T, Zhu W, Zhang J. METTL3 promotes chemoresistance in small cell lung cancer by inducing mitophagy. J Experimental Clin cancer Research: CR. 2023;42(1):65.
72. Liang J Cai H Hou C Song F Jiang Y Wang Z Qiu D Zhu Y Wang F Yu D Hou J METTL14 inhibits malignant progression of oral squamous cell carcinoma by targeting the autophagy-related gene RB1CC1 in an m6A-IGF2BP2-dependent manner Clin Sci (London England: 1979) 2023 137 17 1373 89 10.1042/CS20230219
Liang J, Cai H, Hou C, Song F, Jiang Y, Wang Z, Qiu D, Zhu Y, Wang F, Yu D, Hou J. METTL14 inhibits malignant progression of oral squamous cell carcinoma by targeting the autophagy-related gene RB1CC1 in an m6A-IGF2BP2-dependent manner. Clin Sci (London England: 1979). 2023;137(17):1373–89.
73. Yu H Zhuang J Zhou Z Song Q Lv J Yang X Yang H Lu Q METTL16 suppressed the proliferation and cisplatin-chemoresistance of bladder cancer by degrading PMEPA1 mRNA in a m6A manner through autophagy pathway Int J Biol Sci 2024 20 4 1471 91 10.7150/ijbs.86719 38385084
Yu H, Zhuang J, Zhou Z, Song Q, Lv J, Yang X, Yang H, Lu Q. METTL16 suppressed the proliferation and cisplatin-chemoresistance of bladder cancer by degrading PMEPA1 mRNA in a m6A manner through autophagy pathway. Int J Biol Sci. 2024;20(4):1471–91.38385084
74. Binnewies M Roberts EW Kersten K Chan VA-O Fearon DF Merad M Coussens LM Gabrilovich DI Ostrand-Rosenberg SA-O Hedrick CC Vonderheide RH Pittet MJ Jain RK Zou W Howcroft TK Woodhouse EC Weinberg RA Krummel MA-O Understanding the tumor immune microenvironment (TIME) for effective therapy Nat Med 2018 24 5 541 50 10.1038/s41591-018-0014-x 29686425
Binnewies M, Roberts EW, Kersten K, Chan VA-O, Fearon DF, Merad M, Coussens LM, Gabrilovich DI, Ostrand-Rosenberg SA-O, Hedrick CC, Vonderheide RH, Pittet MJ, Jain RK, Zou W, Howcroft TK, Woodhouse EC, Weinberg RA, Krummel MA-O. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541–50.29686425
75. Singer K, Cheng WC, Kreutz M, Ho PC, Siska P. A.-O., Immunometabolism in cancer at a glance. Dis Model Mech. 2018 Aug 2;11(8):dmm034272.
76. Zhou Y Zhang Y Guo R Li C Sun N Identification of methyltransferase-like protein 11B as a new prognostic biomarker for colorectal cancer through an analysis of The Cancer Genome Atlas J Gastrointest Oncol 2021 12 6 2854 71 10.21037/jgo-21-781 35070413
Zhou Y, Zhang Y, Guo R, Li C, Sun N. Identification of methyltransferase-like protein 11B as a new prognostic biomarker for colorectal cancer through an analysis of the Cancer Genome Atlas. J Gastrointest Oncol. 2021;12(6):2854–71.35070413
77. Xie Y, Xie F, Zhang L, Zhou X, Huang J, Wang F, Jin J, Zhang L, Zeng L, Zhou FA-O. Targeted Anti-tumor Immunotherapy using Tumor infiltrating cells. Adv Sci (Weinh). 2021 Nov;8(22):e2101672.
78. Tay C Tanaka A Sakaguchi S Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy Cancer Cell 2023 Mar 2023 13 3 450 65
Tay C, Tanaka A, Sakaguchi S. Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy. Cancer Cell 2023;41(3):450–65.
79. Turley SJ Cremasco V Astarita JL Immunological hallmarks of stromal cells in the tumour microenvironment Nat Rev Immunol 2015 15 11 669 82 10.1038/nri3902 26471778
Turley SJ, Cremasco V, Astarita JL. Immunological hallmarks of stromal cells in the tumour microenvironment. Nat Rev Immunol. 2015;15(11):669–82.26471778
80. Mohammad HP, Barbash O, Creasy CA-O. Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer. Nat Med. 2019;25(3):403–18.
81. Wang J Yan SA-O Lu H Wang SA-O Xu D A.-O., METTL3 Attenuates LPS-Induced Inflammatory Response in Macrophages via NF-κB Signaling Pathway Mediators Inflamm 2019 Oct 2019 24;2019 3120391
Wang J, Yan SA-O, Lu H, Wang SA-O, Xu D. A.-O., METTL3 attenuates LPS-Induced Inflammatory Response in macrophages via NF-κB signaling pathway. Mediators Inflamm 2019;2019:3120391.
82. Pan QZ Pan K Weng DS Zhao JJ Zhang XF Wang DD Lv L Jiang SS Zheng HX Xia JC Annexin A3 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma Mol Carcinog. 2015 54 8 598 607 10.1002/mc.22126 24375474
Pan QZ, Pan K, Weng DS, Zhao JJ, Zhang XF, Wang DD, Lv L, Jiang SS, Zheng HX, Xia JC. Annexin A3 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma. Mol Carcinog. 2015;54(8):598–607.24375474
83. Zhao Y, Luo Q, Wang W, Geng S, Sun Y, Xu T. METTL16, an evolutionarily conserved m6A methyltransferase member, inhibits the antiviral immune response of miiuy croaker dev comp immunol. 2023;145:104713.
84. Liu Z, Chen Y, Shen T. Evidence based on an Integrative Analysis of Multi-omics Data on METTL7A as a molecular marker in Pan-cancer. Biomolecules 2023;13(2):195.
85. Sakaguchi S, Mikami N, Wing JB, Tanaka A, Ichiyama K, Ohkura N, Regulatory T. Cells and human disease. Annu Rev Immunol. 2020 Apr;26:38:541–66.
86. Hui Z, Zhang J, Zheng Y, Yang L, Yu W, An Y, Wei F, Ren X. Single-cell sequencing reveals the transcriptome and TCR characteristics of pTregs and in vitro expanded iTregs. Front Immunol. 2021;31:12:619932.
87. Liu Y Yuan Y Zhou Z Jiang X He S Wei F Cui Y Yang L Zhao G Mettl14 sustains FOXP3 expression to promote the differentiation and functions of induced-regulatory T cells via the mTOR signaling pathway Immunol Lett 2023 258 35 44 10.1016/j.imlet.2023.04.008 37121553
Liu Y, Yuan Y, Zhou Z, Jiang X, He S, Wei F, Cui Y, Yang L, Zhao G. Mettl14 sustains FOXP3 expression to promote the differentiation and functions of induced-regulatory T cells via the mTOR signaling pathway. Immunol Lett. 2023;258:35–44.37121553
88. Gao Z Xu J Zhang Z Fan Y Xue H Guo X Deng L Wang S Zhao R Zhang P Li G A comprehensive analysis of METTL1 to immunity and stemness in Pan-cancer Front Immunol. 2022 31 13 795240 10.3389/fimmu.2022.795240
Gao Z, Xu J, Zhang Z, Fan Y, Xue H, Guo X, Deng L, Wang S, Zhao R, Zhang P, Li G. A comprehensive analysis of METTL1 to immunity and stemness in Pan-cancer. Front Immunol. 2022;31(13):795240.
89. Ni Z, Sun P, Zheng J, Wu M, Yang C, Cheng M, Yin M, Cui C, Wang G, Yuan L, Gao Q, Li YA-O. JNK Signaling Promotes Bladder Cancer Immune Escape by Regulating METTL3-Mediated m6A Modification of PD-L1 mRNA. Cancer Res. 2022 May 3;82(9):1789–1802.
90. Ai YA-O, Liu S, Luo H, Wu S, Wei H, Tang Z, Li XA-OX, Lv XA-O, Zou C. A.-O., METTL3 intensifies the progress of oral squamous cell Carcinoma via modulating the m6A amount of PRMT5 and PD-L1. J Immunol Res. 2021 Aug 23;2021:6149558.
91. Costa C Wang Y Ly A Hosono Y Murchie E Walmsley CS Huynh T Healy C Peterson R Yanase S Jakubik CT Henderson LE Damon LJ Timonina D Sanidas I Pinto CJ Mino-Kenudson M Stone JR Dyson NJ Ellisen LW Bardia A Ebi H Benes CH Engelman JA Juric D PTEN loss mediates clinical cross-resistance to CDK4/6 and PI3Kα inhibitors in breast Cancer Cancer Discov. 2020 10 1 72 85 10.1158/2159-8290.CD-18-0830 31594766
Costa C, Wang Y, Ly A, Hosono Y, Murchie E, Walmsley CS, Huynh T, Healy C, Peterson R, Yanase S, Jakubik CT, Henderson LE, Damon LJ, Timonina D, Sanidas I, Pinto CJ, Mino-Kenudson M, Stone JR, Dyson NJ, Ellisen LW, Bardia A, Ebi H, Benes CH, Engelman JA, Juric D. PTEN loss mediates clinical cross-resistance to CDK4/6 and PI3Kα inhibitors in breast Cancer. Cancer Discov. 2020;10(1):72–85.31594766
92. Xiong J, He J, Zhu J, Pan J, Liao W, Ye H, Wang H, Song Y, Du Y, Cui B, Xue M, Zheng W, Kong X, Jiang K, Ding K, Lai L, Wang Q. Lactylation-driven METTL3-mediated RNA m(6)a modification promotes immunosuppression of tumor-infiltrating myeloid cells. Mol Cell 2022;82(9):1660–e167710.
93. Chen H Pan Y Zhou Q Liang C Wong CC Zhou Y Huang D Liu W Zhai J Gou H Su H Zhang X Xu H Wang Y Kang W Kei Wu WK Yu J METTL3 inhibits Antitumor Immunity by Targeting m(6)A-BHLHE41-CXCL1/CXCR2 Axis to promote Colorectal Cancer Gastroenterology. 2022 163 4 891 907 10.1053/j.gastro.2022.06.024 35700773
Chen H, Pan Y, Zhou Q, Liang C, Wong CC, Zhou Y, Huang D, Liu W, Zhai J, Gou H, Su H, Zhang X, Xu H, Wang Y, Kang W, Kei Wu WK, Yu J. METTL3 inhibits Antitumor Immunity by Targeting m(6)A-BHLHE41-CXCL1/CXCR2 Axis to promote Colorectal Cancer. Gastroenterology. 2022;163(4):891–907.35700773
94. Zhang H Chai S Chen L Wang Y Cheng Y Fang Q Wu G Wang X Liang W Xiao W MRI features of hepatic sarcomatoid carcinoma different from Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma Front Oncol. 2021 11 611738 10.3389/fonc.2021.611738 34221954
Zhang H, Chai S, Chen L, Wang Y, Cheng Y, Fang Q, Wu G, Wang X, Liang W, Xiao W. MRI features of hepatic sarcomatoid carcinoma different from Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Front Oncol. 2021;11:611738.34221954
95. Zhao X Ma W Li X Li H Li J Li H He F ANXA1 enhances tumor proliferation and migration by regulating epithelial-mesenchymal transition and IL-6/JAK2/STAT3 pathway in papillary thyroid carcinoma J Cancer. 2021 12 5 1295 306 10.7150/jca.52171 33531975
Zhao X, Ma W, Li X, Li H, Li J, Li H, He F. ANXA1 enhances tumor proliferation and migration by regulating epithelial-mesenchymal transition and IL-6/JAK2/STAT3 pathway in papillary thyroid carcinoma. J Cancer. 2021;12(5):1295–306.33531975
96. Yamaoka R Ishii T Kawai T Yasuchika K Miyauchi Y Kojima H Katayama H Ogiso S Fukumitsu K Uemoto S CD90 expression in human intrahepatic cholangiocarcinoma is associated with lymph node metastasis and poor prognosis J Surg Oncol. 2018 118 4 664 74 10.1002/jso.25192 30196535
Yamaoka R, Ishii T, Kawai T, Yasuchika K, Miyauchi Y, Kojima H, Katayama H, Ogiso S, Fukumitsu K, Uemoto S. CD90 expression in human intrahepatic cholangiocarcinoma is associated with lymph node metastasis and poor prognosis. J Surg Oncol. 2018;118(4):664–74.30196535
97. Wang A Sun Y Wang X Yan Z Wang D Zeng L Lu Q M(6)a methyltransferase METTL16 mediates immune evasion of colorectal cancer cells via epigenetically regulating PD-L1 expression Aging (Albany NY). 2023 15 16 8444 57 10.18632/aging.204980 37647025
Wang A, Sun Y, Wang X, Yan Z, Wang D, Zeng L, Lu Q. M(6)a methyltransferase METTL16 mediates immune evasion of colorectal cancer cells via epigenetically regulating PD-L1 expression. Aging (Albany NY). 2023;15(16):8444–57.37647025
98. Jiang Z Zhang W Zeng Z Tang D Li C Cai W Chen Y Li Y Jin Q Zhang X Yin L Liu X Xu Y Dai Y A comprehensive investigation discovered the novel methyltransferase METTL24 as one presumably prognostic gene for kidney renal clear cell carcinoma potentially modulating tumor immune microenvironment Front Immunol 2022 14 926461 10.3389/fimmu.2022.926461
Jiang Z, Zhang W, Zeng Z, Tang D, Li C, Cai W, Chen Y, Li Y, Jin Q, Zhang X, Yin L, Liu X, Xu Y, Dai Y. A comprehensive investigation discovered the novel methyltransferase METTL24 as one presumably prognostic gene for kidney renal clear cell carcinoma potentially modulating tumor immune microenvironment. Front Immunol. 2022;14:13:926461.
99. Ma J Han H Huang Y Yang C Zheng S Cai T Bi J Huang X Liu R Huang L Luo Y Li W Lin S METTL1/WDR4-mediated m(7)G tRNA modifications and m(7)G codon usage promote mRNA translation and lung cancer progression Mol Ther. 2021 29 12 3422 3435 10.1016/j.ymthe.2021.08.005 34371184
Ma J, Han H, Huang Y, Yang C, Zheng S, Cai T, Bi J, Huang X, Liu R, Huang L, Luo Y, Li W, Lin S. METTL1/WDR4-mediated m(7)G tRNA modifications and m(7)G codon usage promote mRNA translation and lung cancer progression. Mol Ther. 2021;29(12):3422–35.34371184
100. Chen Z Zhu W Zhu S Sun K Liao J Liu H Dai Z Han H Ren X Yang Q Zheng S Peng B Peng S Kuang M Lin S A.-O. X., METTL1 promotes hepatocarcinogenesis via m(7) G tRNA modification-dependent translation control Clin Transl Med 2021 11 12 e661 10.1002/ctm2.661 34898034
Chen Z, Zhu W, Zhu S, Sun K, Liao J, Liu H, Dai Z, Han H, Ren X, Yang Q, Zheng S, Peng B, Peng S, Kuang M, Lin S. A.-O. X., METTL1 promotes hepatocarcinogenesis via m(7) G tRNA modification-dependent translation control. Clin Transl Med. 2021;11(12):e661.34898034
101. Cartlidge RA Knebel A Fau - Peggie M Peggie M Fau - Alexandrov A Alexandrov AF Phizicky EM Cohen P Cohen P The tRNA methylase METTL1 is phosphorylated and inactivated by PKB and RSK in vitro and in cells EMBO J 2005 4 9 1696 705 10.1038/sj.emboj.7600648
Cartlidge RA, Knebel A, Fau - Peggie M, Peggie M, Fau - Alexandrov A, Alexandrov AF, Phizicky EM, Cohen P, Cohen P. The tRNA methylase METTL1 is phosphorylated and inactivated by PKB and RSK in vitro and in cells. EMBO J. 2005;4(9):1696–705.
102. Lin S, Liu Q, Lelyveld VS, Choe J, Szostak JW, Gregory RI. Mettl1/Wdr4-Mediated m(7)G tRNA methylome is required for normal mRNA translation and embryonic stem cell Self-Renewal and differentiation. Mol Cell 2018 Jul 19;71(2):244–e2555.
103. Tian QH Zhang MF Zeng JS Luo RG Wen Y Chen J Gan LG Xiong JP METTL1 overexpression is correlated with poor prognosis and promotes hepatocellular carcinoma via PTEN J Mol Med (Berl) 2019 97 11 1535 45 10.1007/s00109-019-01830-9 31463732
Tian QH, Zhang MF, Zeng JS, Luo RG, Wen Y, Chen J, Gan LG, Xiong JP. METTL1 overexpression is correlated with poor prognosis and promotes hepatocellular carcinoma via PTEN. J Mol Med (Berl). 2019;97(11):1535–45.31463732
104. Pandolfini L, Barbieri I, Bannister AJ, Hendrick A, Andrews B, Webster N, Murat P, Mach P, Brandi R, Robson SC, Migliori V, Alendar A, d’Onofrio M, Balasubramanian S, Kouzarides T. METTL1 promotes let-7 MicroRNA Processing via m7G methylation. Mol Cell 2019;74(6):1278–e12909.
105. Huang MA-O Long JA-O Yao ZA-O Zhao YA-O Zhao YA-O Liao JA-O Lei KA-O Xiao HA-O Dai ZA-O Peng SA-O Lin SA-OX Xu LA-O Kuang M A.-O., METTL1-Mediated m7G tRNA Modification Promotes Lenvatinib Resistance in Hepatocellular Carcinoma Cancer Res 2023 4 1 89 102 10.1158/0008-5472.CAN-22-0963
Huang MA-O, Long JA-O, Yao ZA-O, Zhao YA-O, Zhao YA-O, Liao JA-O, Lei KA-O, Xiao HA-O, Dai ZA-O, Peng SA-O, Lin SA-OX, Xu LA-O, Kuang M. A.-O., METTL1-Mediated m7G tRNA modification promotes Lenvatinib Resistance in Hepatocellular Carcinoma. Cancer Res. 2023;4(1):89–102.
106. Chen J Li K Chen J Wang X Ling R Cheng M Chen Z Chen F He Q Li S Zhang C Jiang Y Chen Q Wang A Chen D A.-O., Aberrant translation regulated by METTL1/WDR4-mediated tRNA N7-methylguanosine modification drives head and neck squamous cell carcinoma progression Cancer Commun (Lond) 2022 42 3 223 44 10.1002/cac2.12273 35179319
Chen J, Li K, Chen J, Wang X, Ling R, Cheng M, Chen Z, Chen F, He Q, Li S, Zhang C, Jiang Y, Chen Q, Wang A, Chen D. A.-O., aberrant translation regulated by METTL1/WDR4-mediated tRNA N7-methylguanosine modification drives head and neck squamous cell carcinoma progression. Cancer Commun (Lond). 2022;42(3):223–44.35179319
107. Wang Y, Xiong G, Cai W, Tao Q. METTL1 facilitates ameloblastoma invasive growth via MAPK signaling pathway. Gene.2024 May 5 ;905:148234.
108. Soumoy L Ghanem GE Saussez S Journe F Bufalin for an innovative therapeutic approach against cancer Pharmacol Res 2022 184 106442 10.1016/j.phrs.2022.106442 36096424
Soumoy L, Ghanem GE, Saussez S, Journe F. Bufalin for an innovative therapeutic approach against cancer. Pharmacol Res. 2022;184:106442.36096424
109. Li L Yang Y Wang Z Xu C Huang J Li G A.-O., Prognostic role of METTL1 in glioma Cancer Cell Int 2021 Nov 2021 27 1 633
Li L, Yang Y, Wang Z, Xu C, Huang J, Li G. A.-O., prognostic role of METTL1 in glioma. Cancer Cell Int 2021 Nov 27;21(1):633.
110. Liu KA-O Gao Y Gan K Wu Y Xu B Zhang L Chen M A.-O., Prognostic Roles of N6-Methyladenosine METTL3 in Different Cancers: A System Review and Meta-Analysis Cancer Control 2021 28 1073274821997455 10.1177/1073274821997455 33631954
Liu KA-O, Gao Y, Gan K, Wu Y, Xu B, Zhang L, Chen M. A.-O., Prognostic roles of N6-Methyladenosine METTL3 in different cancers: a System Review and Meta-Analysis. Cancer Control. 2021;28:1073274821997455.33631954
111. Guo Y Heng Y Chen H Huang QA-O Wu C Tao L Zhou L Prognostic Values of METTL3 and Its Roles in Tumor Immune Microenvironment in Pan-Cancer J Clin Med 2022 25 1 155 10.3390/jcm12010155
Guo Y, Heng Y, Chen H, Huang QA-O, Wu C, Tao L, Zhou L. Prognostic values of METTL3 and its roles in Tumor Immune Microenvironment in Pan-cancer. J Clin Med. 2022;25(1):155.
112. Doucet-O'Hare TT Sharma R Rodić N Anders RA Burns KH Kazazian HH Jr. Somatically Acquired LINE-1 Insertions in Normal Esophagus Undergo Clonal Expansion in Esophageal Squamous Cell Carcinoma Hum Mutat 2016 37 9 942 54 10.1002/humu.23027 27319353
Doucet-O’Hare TT, Sharma R, Rodić N, Anders RA, Burns KH, Kazazian HH Jr. Somatically acquired LINE-1 insertions in normal Esophagus Undergo Clonal expansion in esophageal squamous cell carcinoma. Hum Mutat. 2016;37(9):942–54.27319353
113. Hamer PA-O Hight SC Ward IG Harris DL Woodham BL Flint RS Stricture rate after chemoradiotherapy and radiotherapy for oesophageal squamous cell carcinoma: a 20-year experience ANZ J Surg 2019 89 4 367 71 10.1111/ans.14981 30791194
Hamer PA-O, Hight SC, Ward IG, Harris DL, Woodham BL, Flint RS. Stricture rate after chemoradiotherapy and radiotherapy for oesophageal squamous cell carcinoma: a 20-year experience. ANZ J Surg. 2019;89(4):367–71.30791194
114. Zou J Zhong X Zhou X Xie Q Zhao Z Guo X Duan Y The M6A methyltransferase METTL3 regulates proliferation in esophageal squamous cell carcinoma Biochem Biophys Res Commun 2021 Nov 2021 26 48 55 10.1016/j.bbrc.2021.05.048
Zou J, Zhong X, Zhou X, Xie Q, Zhao Z, Guo X, Duan Y. The M6A methyltransferase METTL3 regulates proliferation in esophageal squamous cell carcinoma. Biochem Biophys Res Commun 2021 Nov 26;580:48–55.
115. Guo S Chen F Li L Dou S Li Q Huang Y Li Z Liu W Zhang G Intracellular Fusobacterium nucleatum infection increases METTL3-mediated m6A methylation to promote the metastasis of esophageal squamous cell carcinoma J Adv Res 2024 61 165 78 10.1016/j.jare.2023.08.014 37619934
Guo S, Chen F, Li L, Dou S, Li Q, Huang Y, Li Z, Liu W, Zhang G. Intracellular Fusobacterium nucleatum infection increases METTL3-mediated m6A methylation to promote the metastasis of esophageal squamous cell carcinoma. J Adv Res. 2024;61:165–78.37619934
116. Cheng FW Peng LM Luo D Methyltransferase-like 3 promotes the progression of lung cancer via activating PI3K/AKT/mTOR pathway Clin Exp Pharmacol Physiol 2022 49 7 748 58 10.1111/1440-1681.13647 35434840
Cheng FW, Peng LM, Luo D. Methyltransferase-like 3 promotes the progression of lung cancer via activating PI3K/AKT/mTOR pathway. Clin Exp Pharmacol Physiol. 2022 Jul;49(7):748–58.35434840
117. Xue L, Li J, Lin Y, Liu D, Yang Q, Jian J, Peng JA-O. M(6) a transferase METTL3-induced lncRNA ABHD11-AS1 promotes the Warburg effect of non-small-cell lung cancer. J Cell Physiol. 2021;236(4):2649–58.
118. Yan T, Yu L, Zhang N, Peng C, Su G, Jing Y, Zhang L, Wu T, Cheng J, Guo Q, Shi X, Lu Y. The advanced development of molecular targeted therapy for hepatocellular carcinoma. Cancer Biology Med. 2022;19(6):802–17.
119. Ke W Zhang L Zhao X Lu Z p53 m(6)A modulation sensitizes hepatocellular carcinoma to apatinib through apoptosis Apoptosis 2022 27 5–6 426 40 10.1007/s10495-022-01728-x 35503144
Ke W, Zhang L, Zhao X, Lu Z. p53 m(6)a modulation sensitizes hepatocellular carcinoma to apatinib through apoptosis. Apoptosis. 2022 Jun;27(5–6):426–40.35503144
120. Qi LW Jia JH Jiang CH Hu JM Contributions and Prognostic Values of N6-Methyladenosine RNA Methylation Regulators in Hepatocellular Carcinoma Front Genet 2021 Jan 2021 15 614566
Qi LW, Jia JH, Jiang CH, Hu JM. Contributions and prognostic values of N6-Methyladenosine RNA methylation regulators in Hepatocellular Carcinoma. Front Genet 2021 Jan 15;11:614566.
121. Liu X, Qin J, Gao T, Li C, Chen X, Zeng K, Xu M, He B, Pan B, Xu X, Pan Y, Sun H, Xu T, Wang S. Analysis of METTL3 and METTL14 in hepatocellular carcinoma. Aging (Albany NY). 2020 Nov 6;12(21):21638–21659.
122. Wu A, Hu Y, Xu Y, Xu J, Wang X, Cai A, Liu R, Chen L, Wang F. Methyltransferase-like 3-Mediated m6A methylation of Hsa_circ_0058493 accelerates Hepatocellular Carcinoma Progression by binding to YTH Domain-Containing protein 1. Front Cell Dev Biol. 2021 Nov 23;9:762588.
123. Lan YL, Lou JC, Jiang XW, Wang X, Xing JS, Li S, Zhang B. A research update on the anticancer effects of bufalin and its derivatives. Oncol Lett. 2019;17(4):3635–40.
124. Gao JA-O, Fang Y, Chen J, Tang Z, Tian M, Jiang X, Tao C, Huang R, Zhu GA-O, Qu W, Wu X, Zhou JA-O, Fan JA-OX, Liu WA-O, Shi Y. A.-O., methyltransferase like 3 inhibition limits intrahepatic cholangiocarcinoma metabolic reprogramming and potentiates the efficacy of chemotherapy. Oncogene. 2023;42(33):2507–20.
125. Zhou DA-O, Tang W, Xu Y, Xu Y, Xu B, Fu S, Wang Y, Chen F, Chen Y, Han Y, Wang G. METTL3/YTHDF2 m6A axis accelerates colorectal carcinogenesis through epigenetically suppressing YPEL5. Mol Oncol. 2021 Aug;15(8):2172–84.
126. Yu Z, Li Y, Li Y, Zhang J, Li M, Ji L, Tang Y, Zheng Y, Sheng J, Han Q, Li F, Guo J, Wang L, Sun X, Gao Y, Feng H. Bufalin stimulates antitumor immune response by driving tumor-infiltrating macrophage toward M1 phenotype in hepatocellular carcinoma. J Immunother Cancer. 2022;10(5):e004297.
127. Pan J, Liu F, Xiao X, Xu R, Dai L, Zhu M, Xu H, Xu Y, Zhao A, Zhou W, Dang Y, Ji G. METTL3 promotes colorectal carcinoma progression by regulating the m6A-CRB3-Hippo axis. J Exp Clin Cancer Res 2022 Jan 10;41(1):19.
128. Deng R Cheng Y Ye S Zhang J Huang R Li P Liu H Deng Q Wu X Lan P Deng Y m(6)A methyltransferase METTL3 suppresses colorectal cancer proliferation and migration through p38/ERK pathways Onco Targets Ther 2019 Jun 2019 4 4391 402
Deng R, Cheng Y, Ye S, Zhang J, Huang R, Li P, Liu H, Deng Q, Wu X, Lan P, Deng Y. M(6)a methyltransferase METTL3 suppresses colorectal cancer proliferation and migration through p38/ERK pathways. Onco Targets Ther 2019;12:4391–402.
129. Chen Y Sun L Inhibition of NEDD8 NEDDylation induced apoptosis in acute myeloid leukemia cells via p53 signaling pathway Biosci Rep 2022 42 8 10.1042/BSR20220994
Chen Y, Sun L. Inhibition of NEDD8 NEDDylation induced apoptosis in acute myeloid leukemia cells via p53 signaling pathway. Biosci Rep. 2022;42:8.
130. Liu L, Wu Y, Li Q, Liang J, He Q, Zhao L, Chen J, Cheng M, Huang Z, Ren H, Chen J, Peng L, Gao F, Chen D, Wang A. METTL3 promotes tumorigenesis and metastasis through BMI1 m(6)a methylation in oral squamous cell carcinoma. Mol Ther 2020;28(10):2177–90.
131. Yuan Y Du Y Wang L Liu X The M6A methyltransferase METTL3 promotes the development and progression of prostate carcinoma via mediating MYC methylation J Cancer 2020 25 12 3588 95 10.7150/jca.42338
Yuan Y, Du Y, Wang L, Liu X. The M6A methyltransferase METTL3 promotes the development and progression of prostate carcinoma via mediating MYC methylation. J Cancer. 202025(12):3588–95.
132. Yu F, Yu C, Li F, Zuo Y, Wang Y, Yao L, Wu C, Wang C, Ye L. Wnt/β-catenin signaling in cancers and targeted therapies. Signal Transduct Target Therapy. 2021;6(1):307.
133. Wu F Zhang Y Fang Y Ma S Zheng H Liu K Wang R Elevated Expression of Inhibitor of Apoptosis-stimulating Protein of p53 (iASPP) and Methyltransferase-like 3 (METTL3) Correlate with Poor Prognosis in FIGO Ib1-IIa Squamous Cell Cervical Cancer J Cancer 2020 10 9 2382 9 10.7150/jca.41029
Wu F, Zhang Y, Fang Y, Ma S, Zheng H, Liu K, Wang R. Elevated expression of inhibitor of apoptosis-stimulating protein of p53 (iASPP) and methyltransferase-like 3 (METTL3) correlate with poor prognosis in FIGO Ib1-IIa squamous cell cervical Cancer. J Cancer. 2020;10(9):2382–9.
134. Liu P Ju M Zheng X Jiang Y Yu X Pan B Luo R Jia W Zheng MA-O Methyltransferase-like 3 promotes cervical cancer metastasis by enhancing cathepsin L mRNA stability in an N6-methyladenosine-dependent manner Cancer Sci 2023 114 3 837 54 10.1111/cas.15658 36382580
Liu P, Ju M, Zheng X, Jiang Y, Yu X, Pan B, Luo R, Jia W, Zheng MA-O. Methyltransferase-like 3 promotes cervical cancer metastasis by enhancing cathepsin L mRNA stability in an N6-methyladenosine-dependent manner. Cancer Sci. 2023;114(3):837–54.36382580
135. Zhang HM Qi FF Wang J Duan YY Zhao LL Wang YD Zhang TC Liao XH The m6A Methyltransferase METTL3-Mediated N6-Methyladenosine Modification of DEK mRNA to Promote Gastric Cancer Cell Growth and Metastasis Int J Mol Sci 2022 Jun 2022 9 12 6451
Zhang HM, Qi FF, Wang J, Duan YY, Zhao LL, Wang YD, Zhang TC, Liao XH. The m6A methyltransferase METTL3-Mediated N6-Methyladenosine modification of DEK mRNA to promote gastric Cancer cell growth and metastasis. Int J Mol Sci 2022 Jun 9;23(12):6451.
136. Xia TL Yan SA-O Yuan L Zeng MS Upregulation of METTL3 Expression Predicts Poor Prognosis in Patients with Esophageal Squamous Cell Carcinoma Cancer Manag Res 2020 Jul 2020 13 5729 37
Xia TL, Yan SA-O, Yuan L, Zeng MS. Upregulation of METTL3 expression predicts poor prognosis in patients with esophageal squamous cell carcinoma. Cancer Manag Res 2020 Jul 13;12:5729–37.
137. Gao Q, Yu GY, Shi JY, Li LH, Zhang WJ, Wang ZC, Yang LX, Duan M, Zhao H, Wang XY, Zhou J, Qiu SJ, Jeong LS, Jia LJ, Fan J. Neddylation pathway is up-regulated in human intrahepatic cholangiocarcinoma and serves as a potential therapeutic target. Oncotarget. 2014;5(17):7820–32.
138. Liu GA-O Zeng HD Zhang CY Xu JW Identification of METTL3 as an Adverse Prognostic Biomarker in Hepatocellular Carcinoma Dig Dis Sci 2021 66 4 1110 26 10.1007/s10620-020-06260-z 32333311
Liu GA-O, Zeng HD, Zhang CY, Xu JW. Identification of METTL3 as an adverse prognostic biomarker in Hepatocellular Carcinoma. Dig Dis Sci. 2021;66(4):1110–26.32333311
139. Yue B Song C Yang L Cui R Cheng X Zhang Z Zhao G METTL3-mediated N6-methyladenosine modification is critical for epithelial-mesenchymal transition and metastasis of gastric cancer Mol Cancer 2019 13 1 142 10.1186/s12943-019-1065-4
Yue B, Song C, Yang L, Cui R, Cheng X, Zhang Z, Zhao G. METTL3-mediated N6-methyladenosine modification is critical for epithelial-mesenchymal transition and metastasis of gastric cancer. Mol Cancer. 2019;13(1):142.
140. Du QY, Huo FC, Du WQ, Sun XL, Jiang X, Zhang LA-O, Pei D. A.-O., METTL3 potentiates progression of cervical cancer by suppressing ER stress via regulating m6A modification of TXNDC5 mRNA. Oncogene. 2022;41(39):4420–32.
141. Zhu D, Liu Y, Chen J, Wang Q, Li Y, Zhu Y, Feng J, Jiang JA-O. The methyltransferase METTL3 promotes tumorigenesis via mediating HHLA2 mRNA m6A modification in human renal cell carcinoma. J Transl Med. 2022 Jul 6;20(1):298.
142. Qiu LW Liu YF Cao XQ Wang Y Cui XH Ye X Huang SW Xie HJ Zhang HJ Annexin A2 promotion of hepatocellular carcinoma tumorigenesis via the immune microenvironment World J Gastroenterol 2020 26 18 2126 37 10.3748/wjg.v26.i18.2126 32476780
Qiu LW, Liu YF, Cao XQ, Wang Y, Cui XH, Ye X, Huang SW, Xie HJ, Zhang HJ. Annexin A2 promotion of hepatocellular carcinoma tumorigenesis via the immune microenvironment. World J Gastroenterol. 2020;26(18):2126–37.32476780
143. Ali J, Liu W, Duan W, Liu C, Song J, Ali S, Li E, Wang Q. METTL7B (methyltransferase-like 7B) identification as a novel biomarker for lung adenocarcinoma. Ann Transl Med. 2020;8(18):1130.
144. Liu D Li W Zhong F Yin J Zhou W Li S Sun X Xu J Li G Wen Y Wang J Hong M Cheng Z Yuan J Dai L Sun J Wang J Qiu C Wang G Zou C METTL7B Is Required for Cancer Cell Proliferation and Tumorigenesis in Non-Small Cell Lung Cancer Front Pharmacol 2020 28 178 10.3389/fphar.2020.00178
Liu D, Li W, Zhong F, Yin J, Zhou W, Li S, Sun X, Xu J, Li G, Wen Y, Wang J, Hong M, Cheng Z, Yuan J, Dai L, Sun J, Wang J, Qiu C, Wang G, Zou C. METTL7B is required for Cancer Cell Proliferation and Tumorigenesis in Non-small Cell Lung Cancer. Front Pharmacol. 2020;28:11:178.
145. Jiang Z, Yin W, Zhu H, Tan J, Guo Y, Xin Z, Zhou Q, Cao Y, Wu Z, Kuang Y, Li C, Xie D, Huang H, Zhao M, Jiang XA-O, Wang L, Ren C. METTL7B is a novel prognostic biomarker of lower-grade glioma based on pan-cancer analysis. Cancer Cell Int. 2021 Jul 19;21(1):383.
146. Pedersen MT Jensen KB Cell biology: Unconventional translation in cancer Nat 2017 Jan 2017 11 7638 471 2
Pedersen MT, Jensen KB. Cell biology: unconventional translation in cancer. Nat 2017 Jan 11;541(7638):471–2.
147. Lindqvist LM Tandoc K Topisirovic I Furic L Cross-talk between protein synthesis, energy metabolism and autophagy in cancer Curr Opin Genet Dev 2018 48 104 11 10.1016/j.gde.2017.11.003 29179096
Lindqvist LM, Tandoc K, Topisirovic I, Furic L. Cross-talk between protein synthesis, energy metabolism and autophagy in cancer. Curr Opin Genet Dev. 2018 Feb;48:104–11.29179096
148. Talavera AA-O, Hendrix JA-O, Versées W, Jurėnas DA-O, Van Nerom K, Vandenberk NA-O, Singh RA-O, Konijnenberg A, De Gieter S, Castro-Roa D, Barth AA-O, De Greve H, Sobott FA-O, Hofkens JA-O, Zenkin NA-O, Loris RA-O, Garcia-Pino AA-O. Phosphorylation decelerates conformational dynamics in bacterial translation elongation factors. Sci Adv. 2018 Mar 14;4(3):eaap9714.
149. Hamey JJ, Wilkins MR. Methylation of elongation factor 1A: where, who, and why? Trends Biochem Sci. 2018;43(3):211–23.
150. Liu Z, Sun T, Piao C, Zhang Z, Kong C. A.-O., METTL13 inhibits progression of clear cell renal cell carcinoma with repression on PI3K/AKT/mTOR/HIF-1α pathway and c-Myc expression. J Transl Med. 2021 May 13;19(1):209.
151. Chai X, Wang J, Li H, Gao C, Li S, Wei C, Huang J, Tian Y, Yuan J, Lu J, Gao D, Zheng Y, Huang C, Zhou J, Shi G, Ke A, Liu F, Fan J, Cai J. Intratumor microbiome features reveal antitumor potentials of intrahepatic cholangiocarcinoma. Gut Microbes. 2023;15(1):2156255.
152. Luo A Yang L Li M Cai M Huang A Liu X Yang X Yan Y Wang X Wu X Huang K Huang L Liu S Xu L Liu X Genetic Variants in METTL14 are Associated with the Risk of Acute Lymphoblastic Leukemia in Southern Chinese Children: A Five-Center Case-Control Study Cancer Manag Res 2021 14 9189 200 10.2147/CMAR.S335925
Luo A, Yang L, Li M, Cai M, Huang A, Liu X, Yang X, Yan Y, Wang X, Wu X, Huang K, Huang L, Liu S, Xu L, Liu X. Genetic variants in METTL14 are Associated with the risk of Acute Lymphoblastic Leukemia in Southern Chinese children: a five-Center Case-Control Study. Cancer Manag Res. 2021;14:13:9189–200.
153. Liang J Cai H Hou C Song F Jiang Y Wang ZA-O Qiu D Zhu Y Wang F Yu D Hou J A.-O., METTL14 inhibits malignant progression of oral squamous cell carcinoma by targeting the autophagy-related gene RB1CC1 in an m6A-IGF2BP2-dependent manner Clin Sci (Lond) 2023 13 17 1373 89 10.1042/CS20230219
Liang J, Cai H, Hou C, Song F, Jiang Y, Wang ZA-O, Qiu D, Zhu Y, Wang F, Yu D, Hou J. A.-O., METTL14 inhibits malignant progression of oral squamous cell carcinoma by targeting the autophagy-related gene RB1CC1 in an m6A-IGF2BP2-dependent manner. Clin Sci (Lond). 2023;13(17):1373–89.
154. Cheng W, Cui C, Liu G, Ye C, Shao F, Bagchi AK, Mehta JL, Wang X. NF-κB, a potential therapeutic target in Cardiovascular diseases. Cardiovasc Drugs Ther. 2023;37(3):571–84.
155. Xu D Han S Yue X Xu X Huang TA-O METTL14 Suppresses Tumor Stemness and Metastasis of Colon Cancer Cells by Modulating m6A-Modified SCD1. LID – 10.1007/s12033-023-00843-7 [doi] Mol Biotechnol 2024 66 8 2095 105 10.1007/s12033-023-00843-7 37592151
Xu D, Han S, Yue X, Xu X, Huang TA-O. METTL14 suppresses tumor stemness and metastasis of Colon cancer cells by modulating m6A-Modified SCD1. LID – 10.1007/s12033-023-00843-7 [doi]. Mol Biotechnol. 2024 Aug;66(8):2095–105.37592151
156. Yao Q, He L, Gao X, Tang N, Lin L, Yu X, Wang D. The m6A Methyltransferase METTL14-Mediated N6-Methyladenosine Modification of PTEN mRNA Inhibits Tumor Growth and Metastasis in Stomach Adenocarcinoma. Front Oncol. 2021 Aug 12;11:699749.
157. Wang S Zou X Chen Y Cho WC Zhou X Effect of N6-Methyladenosine Regulators on Progression and Prognosis of Triple-Negative Breast Cancer Front Genet 2021 28 580036 10.3389/fgene.2020.580036
Wang S, Zou X, Chen Y, Cho WC, Zhou X. Effect of N6-Methyladenosine regulators on Progression and Prognosis of Triple-negative breast Cancer. Front Genet. 2021;28:11:580036.
158. Zhao H Xu Y Xie Y Zhang L Gao M Li S Wang F m6A Regulators Is Differently Expressed and Correlated With Immune Response of Esophageal Cancer Cell Dev Biol 2021 4 650023
Zhao H, Xu Y, Xie Y, Zhang L, Gao M, Li S, Wang F. m6A regulators is differently expressed and correlated with Immune Response of Esophageal Cancer. Cell Dev Biol. 2021;4:9:650023.
159. Zhuo Z, Hua RX, Zhang H, Lin H, Fu W, Zhu J, Cheng J, Zhang J, Li S, Zhou H, Xia H, Liu G, Jia W, He J. METTL14 gene polymorphisms decrease Wilms tumor susceptibility in Chinese children. BMC Cancer. 2021;4(1):1294.
160. Guan Q, Lin H, Miao L, Guo H, Chen Y, Zhuo Z, He JA-O. Functions, mechanisms, and therapeutic implications of METTL14 in human cancer. J Hematol Oncol. 2022 Feb 3;15(1):13.
161. Yi D Wang R Shi X Xu L Yilihamu Y Sang J METTL14 promotes the migration and invasion of breast cancer cells by modulating N6–methyladenosine and hsa–miR–146a–5p expression Oncol Rep 2020 43 5 1375 86 32323801
Yi D, Wang R, Shi X, Xu L, Yilihamu Y, Sang J. METTL14 promotes the migration and invasion of breast cancer cells by modulating N6–methyladenosine and hsa–miR–146a–5p expression. Oncol Rep. 2020;43(5):1375–86.32323801
162. You L, Lin J, Yu Z, Qian Y, Bi Y, Wang F, Zhang L, Zheng C, Zhang J, Li W, Cai Y, Gao Y, Kong X, Sun X. Nobiletin suppresses cholangiocarcinoma proliferation via inhibiting GSK3β. Int J Biol Sci. 2022;18(15):5698–712.
163. Peng F, Xu J, Cui B, Liang Q, Zeng S, He B, Zou H, Li M, Zhao H, Meng Y, Chen J, Liu B, Lv S, Chu P, An F, Wang ZA-O, Huang J, Zhan Y, Liao Y, Lu J, Xu L, Zhang J, Sun Z, Li Z, Wang F, Lam EA-O, Liu Q. Oncogenic AURKA-enhanced N(6)-methyladenosine modification increases DROSHA mRNA stability to transactivate STC1 in breast cancer stem-like cells. Cell Res. 2021;31(3):345–61.
164. Xiao H Fan X Zhang R Wu G Upregulated N6-Methyladenosine RNA in Peripheral Blood: Potential Diagnostic Biomarker for Breast Cancer Cancer Res Treat 2021 53 2 399 408 10.4143/crt.2020.870 33138349
Xiao H, Fan X, Zhang R, Wu G. Upregulated N6-Methyladenosine RNA in Peripheral blood: potential diagnostic biomarker for breast Cancer. Cancer Res Treat. 2021;53(2):399–408.33138349
165. Gatza ML Silva GO Parker JS Fan C Perou CM An integrated genomics approach identifies drivers of proliferation in luminal-subtype human breast cancer Nat Genet 2014 46 10 1051 9 10.1038/ng.3073 25151356
Gatza ML, Silva GO, Parker JS, Fan C, Perou CM. An integrated genomics approach identifies drivers of proliferation in luminal-subtype human breast cancer. Nat Genet. 2014 Oct;46(10):1051–9.25151356
166. Wang S Li H Liu J Zhang Q Xu W Xiang J Fang L Xu P Li ZA-O Integrative analysis of m3C associated genes reveals METTL2A as a potential oncogene in breast Cancer J Transl Med 2022 20 1 476 10.1186/s12967-022-03683-2 36266694
Wang S, Li H, Liu J, Zhang Q, Xu W, Xiang J, Fang L, Xu P, Li ZA-O. Integrative analysis of m3C associated genes reveals METTL2A as a potential oncogene in breast Cancer. J Transl Med. 2022;20(1):476.36266694
167. Xu W Liu S Zhang G Liu J Cao G Knockdown of METTL5 inhibits the Myc pathway to downregulate PD-L1 expression and inhibits immune escape of hepatocellular carcinoma cells J Chemother 2023 35 5 455 64 10.1080/1120009X.2022.2143614 36369791
Xu W, Liu S, Zhang G, Liu J, Cao G. Knockdown of METTL5 inhibits the Myc pathway to downregulate PD-L1 expression and inhibits immune escape of hepatocellular carcinoma cells. J Chemother. 2023 Sep;35(5):455–64.36369791
168. Bolatkan A, Asada K, Kaneko S, Suvarna K, Ikawa N, Machino H, Komatsu M, Shiina S, Hamamoto R. Downregulation of METTL6 mitigates cell progression, migration, invasion and adhesion in hepatocellular carcinoma by inhibiting cell adhesion molecules. LID – 4 [pii] LID – 10.3892/ijo.2021.5294 [doi]. Int J Oncol. 2022 Jan;60(1):4.
169. Dai YZ Liu YD Li J Chen MT Huang M Wang F Yang QS Yuan JA-O Sun SH METTL16 promotes hepatocellular carcinoma progression through downregulating RAB11B-AS1 in an m(6)A-dependent manner Cell Mol Biol Lett 2022 20 1 41 10.1186/s11658-022-00342-8
Dai YZ, Liu YD, Li J, Chen MT, Huang M, Wang F, Yang QS, Yuan JA-O, Sun SH. METTL16 promotes hepatocellular carcinoma progression through downregulating RAB11B-AS1 in an m(6)A-dependent manner. Cell Mol Biol Lett. 2022;20(1):41.
170. Yu H Zhuang J Zhou Z Song Q Lv J Yang X Yang H Lu Q METTL16 suppressed the proliferation and cisplatin-chemoresistance of bladder cancer by degrading PMEPA1 mRNA in a m6A manner through autophagy pathway Int J Biol Sci 2024 20 4 1471 91 10.7150/ijbs.86719 38385084
Yu H, Zhuang J, Zhou Z, Song Q, Lv J, Yang X, Yang H, Lu Q. METTL16 suppressed the proliferation and cisplatin-chemoresistance of bladder cancer by degrading PMEPA1 mRNA in a m6A manner through autophagy pathway. Int J Biol Sci. 2024 Feb;20(4):1471–91.38385084
171. Lambert LK Horrill TC Beck SM Bourgeois A Browne AJ Cheng S Howard AF Kaur J McKenzie M Stajduhar KI Thorne S Health and healthcare equity within the Canadian cancer care sector: a rapid scoping review Int J Equity Health 2023 Jan 2023 22 1 20 10.1186/s12939-023-01829-2
Lambert LK, Horrill TC, Beck SM, Bourgeois A, Browne AJ, Cheng S, Howard AF, Kaur J, McKenzie M, Stajduhar KI, Thorne S. Health and healthcare equity within the Canadian cancer care sector: a rapid scoping review. Int J Equity Health 2023;22(1):20.
172. Jönsson B. Cost of Cancer: Healthcare expenditures and Economic Impact. Recent Results Cancer Res. 2019;213:7–23.
173. Szász AM Győrffy B Marko-Varga G Cancer heterogeneity determined by functional proteomics Semin Cell Dev Biol 2017 64 132 42 10.1016/j.semcdb.2016.08.026 27569188
Szász AM, Győrffy B, Marko-Varga G. Cancer heterogeneity determined by functional proteomics. Semin Cell Dev Biol. 2017 Apr;64:132–42.27569188
174. Okamoto M, Fujiwara M, Hori M, Okada K, Yazama F, Konishi H, Xiao Y, Qi G, Shimamoto F, Ota T, Temme A, Tatsuka M. tRNA modifying enzymes, NSUN2 and METTL1, determine sensitivity to 5-fluorouracil in HeLa cells. PLoS Genet. 2014 Sep 18;10(9):e1004639.
175. Liu C Li N Liu G Feng X Annexin A3 and cancer Oncol Lett 2021 22 6 834 10.3892/ol.2021.13095 34712358
Liu C, Li N, Liu G, Feng X. Annexin A3 and cancer. Oncol Lett. 2021;22(6):834.34712358
176. Issahaku AR, Mncube SM, Agoni C, Kwofie SK, Alahmdi MI, Abo-Dya NE, Sidhom PA, Tawfeek AM, Ibrahim MAA, Mukelabai N, Soremekun O, Soliman MES. Multi-dimensional structural footprint identification for the design of potential scaffolds targeting METTL3 in cancer treatment from natural compounds. J Mol Model. 2023 Mar 30;29(4):122.
177. Pan X, Hong X, Li S, Meng P, Xiao F. METTL3 promotes adriamycin resistance in MCF-7 breast cancer cells by accelerating pri-microRNA-221-3p maturation in a m6A-dependent manner.
178. Ouyang D, Hong T, Fu M, Li Y, Zeng L, Chen Q, He H, Wen Y, Cheng Y, Zhou M, Zou Q, Yi W. A.-O., METTL3 depletion contributes to tumour progression and drug resistance via N6 methyladenosine-dependent mechanism in HR + HER2-breast cancer. Exp Mol Med. 2021;53(1):91–102.
179. Li H, Wang C, Lan L, Yan L, Li W, Evans I, Ruiz EJ, Su Q, Zhao G, Wu W, Zhang H, Zhou Z, Hu Z, Chen W, Oliveira JM, Behrens AA-O, Reis RL, Zhang C. METTL3 promotes oxaliplatin resistance of gastric cancer CD133 + stem cells by promoting PARP1 mRNA stability. Cell Mol Life Sci. 2022 Feb 18;79(3):135.
180. Zhang K Zhang T Yang Y Tu W Huang H Wang Y Chen Y Pan K Chen Z N(6)-methyladenosine-mediated LDHA induction potentiates chemoresistance of colorectal cancer cells through metabolic reprogramming Theranostics 2022 13 10 4802 17 10.7150/thno.73746
Zhang K, Zhang T, Yang Y, Tu W, Huang H, Wang Y, Chen Y, Pan K, Chen Z. N(6)-methyladenosine-mediated LDHA induction potentiates chemoresistance of colorectal cancer cells through metabolic reprogramming. Theranostics 2022;12(10):4802–17.
181. Selberg S Blokhina D Aatonen M Koivisto P Siltanen A Mervaala E Kankuri E Karelson M Discovery of Small Molecules that Activate RNA Methylation through Cooperative Binding to the METTL3-14-WTAP Complex Active Site Cell Rep 2019 26 13 3762 e37715 10.1016/j.celrep.2019.02.100 30917327
Selberg S, Blokhina D, Aatonen M, Koivisto P, Siltanen A, Mervaala E, Kankuri E, Karelson M. Discovery of Small molecules that activate RNA methylation through Cooperative binding to the METTL3-14-WTAP complex active site. Cell Rep. 2019 Mar;26(13):3762–e37715.30917327
182. Pan S Deng Y Fu J Zhang Y Zhang Z Qin X N6–methyladenosine upregulates miR–181d–5p in exosomes derived from cancer–associated fibroblasts to inhibit 5–FU sensitivity by targeting NCALD in colorectal cancer. LID – 14 [pii] LID – 10.3892/ijo.2022.5304 [doi] Int J Oncol 2022 60 2 14 10.3892/ijo.2022.5304 35014676
Pan S, Deng Y, Fu J, Zhang Y, Zhang Z, Qin X. N6–methyladenosine upregulates miR–181d–5p in exosomes derived from cancer–associated fibroblasts to inhibit 5–FU sensitivity by targeting NCALD in colorectal cancer. LID – 14 [pii] LID – 10.3892/ijo.2022.5304 [doi]. Int J Oncol. 2022;60(2):14.35014676
183. Shao C Han Y Huang Y Zhang Z Gong T Zhang Y Tian X Fang M Han X Li M Targeting key RNA methylation enzymes to improve the outcome of colorectal cancer chemotherapy (Review). LID – 17 [pii] LID – 10.3892/ijo.2023.5605 [doi] Int J Oncol 2024 64 2 17 10.3892/ijo.2023.5605 38131226
Shao C, Han Y, Huang Y, Zhang Z, Gong T, Zhang Y, Tian X, Fang M, Han X, Li M. Targeting key RNA methylation enzymes to improve the outcome of colorectal cancer chemotherapy (review). LID – 17 [pii] LID – 10.3892/ijo.2023.5605 [doi]. Int J Oncol. 2024;64(2):17.38131226
184. Dekker E Tanis PJ Vleugels JLA Kasi PM Wallace MB Colorectal cancer Lancet 2019 19 10207 1467 80 10.1016/S0140-6736(19)32319-0
Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. Lancet. 2019;19(10207):1467–80.
185. Shi L, Gong Y, Zhuo L, Wang S, Chen S, Ke B. Methyltransferase-like 3 upregulation is involved in the chemoresistance of non-small cell lung cancer. Ann Transl Med. 2022;10(3):139.
186. Hernandez BY Zhu X Goodman MT Gatewood R Mendiola P Quinata K Paulino YC Betel nut chewing, oral premalignant lesions, and the oral microbiome PLoS One. 2017 12 2 e0172196 10.1371/journal.pone.0172196 28225785
Hernandez BY, Zhu X, Goodman MT, Gatewood R, Mendiola P, Quinata K, Paulino YC. Betel nut chewing, oral premalignant lesions, and the oral microbiome. PLoS One. 2017;12(2):e0172196.28225785
187. Wang C, Kadigamuwa CA-O, Wu S, Gao YA-O, Chen W, Gu Y, Wang S, Li X. RNA N6-Methyladenosine (m6A) methyltransferase-like 3 facilitates Tumorigenesis and Cisplatin Resistance of Arecoline-exposed oral carcinoma. LID – 10.3390/cells11223605 [doi] LID – 3605. Cells. 2022 Nov;14(22):3605.
188. Zhang H, Zhang Z, Guo T, Chen G, Liu G, Song Q, Li G, Xu F, Dong X, Yang F, Cao C, Zhong D, Li S, Li Y, Wang M, Li B, Yang L. Annexin A protein family: focusing on the occurrence, progression and treatment of cancer. Front cell Dev Biology. 2023;11:1141331.
189. Cui SA-O METTL3-mediated m6A modification of lnc RNA RHPN1-AS1 enhances cisplatin resistance in ovarian cancer by activating PI3K/AKT pathway J Clin Lab Anal 2022 36 12 e24761 10.1002/jcla.24761 36336887
Cui SA-O. METTL3-mediated m6A modification of lnc RNA RHPN1-AS1 enhances cisplatin resistance in ovarian cancer by activating PI3K/AKT pathway. J Clin Lab Anal. 2022;36(12):e24761.36336887
190. Li H, Zhang Q, Feng Q, You Q, Guo X. The development of small molecules targeting methyltransferase-like 3. Drug Discov Today. 2023;28(4):103513.
191. Kumar SK Rajkumar V Kyle RA van Duin M Sonneveld P Mateos MV Gay F Anderson KC Multiple myeloma JAMA. 2022 327 5 464 477 10.1001/jama.2022.0003 35103762
Kumar SK, Rajkumar V, Kyle RA, van Duin M, Sonneveld P, Mateos MV, Gay F, Anderson KC. Multiple myeloma. JAMA. 2022;327(5):464–77.35103762
192. Robak P Drozdz I Szemraj J Robak T Drug resistance in multiple myeloma N Engl J Med 2023 27 4 335 47
Robak P, Drozdz I, Szemraj J, Robak T. Drug resistance in multiple myeloma. N Engl J Med. 2023;27(4):335–47.
193. Trotter TN Gibson JT Sherpa TL Gowda PS Peker D Yang Y Adipocyte-Lineage Cells Support Growth and Dissemination of Multiple Myeloma in Bone Am J Pathol 2016 186 11 3054 63 10.1016/j.ajpath.2016.07.012 27648615
Trotter TN, Gibson JT, Sherpa TL, Gowda PS, Peker D, Yang Y. Adipocyte-Lineage Cells Support Growth and Dissemination of Multiple Myeloma in Bone. Am J Pathol. 2016;186(11):3054–63.27648615
194. Wang Z, He J, Bach DH, Huang YH, Li Z, Liu H, Lin P, Yang J. Induction of m(6)A methylation in adipocyte exosomal LncRNAs mediates myeloma drug resistance. J Exp Clin Cancer Res. 2022 Jan 3;41(1):4.
195. Sun K, Chen L, Li Y, Huang B, Yan Q, Wu C, Lai Q, Fang Y, Cai J, Liu YA-O, Chen J, Wang X, Zhu Y, Dong S, Tan J, Li A, Liu SA-O, Zhang Y. A.-O., METTL14-dependent maturation of pri-miR-17 regulates mitochondrial homeostasis and induces chemoresistance in colorectal cancer. Cell Death Dis. 2023 Feb 21;14(2):148.
196. Luo M Huang Z Yang X Chen Y Jiang J Zhang L Zhou L Qin S Jin P Fu S Peng L Li B Fang Y Pu W Gong Y Liu Y Ren Z Liu QL Wang C Xiao F He D Zhang H Li C Xu H Dai L Peng Y Zhou ZG Huang C Chen HN PHLDB2 mediates Cetuximab Resistance via Interacting with EGFR in Latent Metastasis of Colorectal Cancer Cell Mol Gastroenterol Hepatol 2022 13 4 1223 42 10.1016/j.jcmgh.2021.12.011 34952201
Luo M, Huang Z, Yang X, Chen Y, Jiang J, Zhang L, Zhou L, Qin S, Jin P, Fu S, Peng L, Li B, Fang Y, Pu W, Gong Y, Liu Y, Ren Z, Liu QL, Wang C, Xiao F, He D, Zhang H, Li C, Xu H, Dai L, Peng Y, Zhou ZG, Huang C, Chen HN. PHLDB2 mediates Cetuximab Resistance via Interacting with EGFR in Latent Metastasis of Colorectal Cancer. Cell Mol Gastroenterol Hepatol. 2022;13(4):1223–42.34952201
197. Herbst RS Morgensztern D Boshoff C The biology and management of non-small cell lung cancer Nat 2018 Jan 2018 24 7689 446 54
Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nat 2018 Jan. 2018;24(7689):446–54.
198. Shi XY, Tao XF-, Wang GW, Wang GF, He JF, He JF, Wu LF; Wu Lf Fau - Sun, Sun YZ, Sun XJ. X. J., LncDBH-AS1 knockdown enhances proliferation of non-small cell lung cancer cells by activating the Wnt signaling pathway via the miR-155/AXIN1 axis. Eur Rev Med Pharmacol Sci. 2021 Jan;25(1):139–144.
199. Zhang S, Li H, Li L, Gao Q, Gu L, Hu C, Chen M, Zhang X. Ophiopogonin B inhibits migration and invasion in non-small cell lung cancer cells through enhancing the interaction between Axin and β-catenin. J Cancer. 2021;12(20):6274–84.
200. Gong S Wang S Shao MA-O Mechanism of METTL14-mediated m(6)A modification in non-small cell lung cancer cell resistance to cisplatin J Mol Med (Berl) 2022 100 12 1771 85 10.1007/s00109-022-02268-2 36352154
Gong S, Wang S, Shao MA-O. Mechanism of METTL14-mediated m(6)A modification in non-small cell lung cancer cell resistance to cisplatin. J Mol Med (Berl). 2022;100(12):1771–85.36352154
201. Kong F Liu X Zhou Y Hou X He J Li Q Miao X Yang L Downregulation of METTL14 increases apoptosis and autophagy induced by cisplatin in pancreatic cancer cells Int J Biochem Cell Biol 2020 122 105731 10.1016/j.biocel.2020.105731 32097728
Kong F, Liu X, Zhou Y, Hou X, He J, Li Q, Miao X, Yang L. Downregulation of METTL14 increases apoptosis and autophagy induced by cisplatin in pancreatic cancer cells. Int J Biochem Cell Biol. 2020;122:105731.32097728
202. Zhang C, Ou S, Zhou Y, Liu P, Zhang P, Li Z, Xu R, Li Y. m(6)A Methyltransferase METTL14-Mediated Upregulation of Cytidine Deaminase Promoting Gemcitabine Resistance in Pancreatic Cancer. Front Oncol. 2021;11:696371.
203. Liu Y, Yang C, Zhao Y, Chi Q, Wang Z, Sun B. Overexpressed methyltransferase-like 1 (METTL1) increased chemosensitivity of colon cancer cells to cisplatin by regulating miR-149-3p/S100A4/p53 axis. Aging (Albany NY). 2019;11(24):12328–44.
204. Sun Y Li S Yu W Zhao Z Gao J Chen C Wei M Liu T Li L Liu L N(6)-methyladenosine-dependent pri-miR-17-92 maturation suppresses PTEN/TMEM127 and promotes sensitivity to everolimus in gastric cancer Cell Death Dis 2020 9 10 836 10.1038/s41419-020-03049-w
Sun Y, Li S, Yu W, Zhao Z, Gao J, Chen C, Wei M, Liu T, Li L, Liu L. N(6)-methyladenosine-dependent pri-miR-17-92 maturation suppresses PTEN/TMEM127 and promotes sensitivity to everolimus in gastric cancer. Cell Death Dis. 2020;9(10):836.
205. Gong J, Wang C, Zhang F, Lan W. Effects of Allocryptopine on the proliferation and Epithelial-Mesenchymal Transition of Oral Squamous Cell Carcinoma through m6A mediated hedgehog signaling pathway. J Environ Pathol Toxicol Oncol. 2022;41(2):15–24.
206. Motawi TK El-Maraghy SA Sabry D Nady OM Senousy MA Cromolyn chitosan nanoparticles reverse the DNA methylation of RASSF1A and p16 genes and mitigate DNMT1 and METTL3 expression in breast cancer cell line and tumor xenograft model in mice Chem Biol Interact 2022 25 110094 10.1016/j.cbi.2022.110094
Motawi TK, El-Maraghy SA, Sabry D, Nady OM, Senousy MA. Cromolyn chitosan nanoparticles reverse the DNA methylation of RASSF1A and p16 genes and mitigate DNMT1 and METTL3 expression in breast cancer cell line and tumor xenograft model in mice. Chem Biol Interact. 2022;25:110094.
207. Du MG, Peng ZQ, Gai WB, Liu F, Liu W, Chen YJ, Li HC, Zhang X, Liu CH, Zhang LQ, Jiang H, Xie P. The absence of PTEN in breast Cancer is a driver of MLN4924 Resistance. Front cell Dev Biology. 2021;9:667435.
208. Xu X Zhang PA-O Huang Y Shi W Mao J Ma N Kong L Guo LA-O Liu J Chen J Lu R METTL3-mediated m6A mRNA contributes to the resistance of carbon-ion radiotherapy in non-small-cell lung cancer Cancer Sci 2023 114 1 105 14 10.1111/cas.15590 36114749
Xu X, Zhang PA-O, Huang Y, Shi W, Mao J, Ma N, Kong L, Guo LA-O, Liu J, Chen J, Lu R. METTL3-mediated m6A mRNA contributes to the resistance of carbon-ion radiotherapy in non-small-cell lung cancer. Cancer Sci. 2023;114(1):105–14.36114749
209. Fiorentino FA-O Menna M Rotili DA-O Valente SA-OX Mai A A.-O., METTL3 from Target Validation to the First Small-Molecule Inhibitors: A Medicinal Chemistry Journey J Med Chem 2023 9 3 1654 77 10.1021/acs.jmedchem.2c01601
Fiorentino FA-O, Menna M, Rotili DA-O, Valente SA-OX, Mai A. A.-O., METTL3 from Target Validation to the First Small-Molecule Inhibitors: A Medicinal Chemistry Journey. J Med Chem. 2023;9(3):1654–77.
210. Xu P Ge R Roles and drug development of METTL3 (methyltransferase-like 3) in anti-tumor therapy Eur J Med Chem 2022 15 114118 10.1016/j.ejmech.2022.114118
Xu P, Ge R. Roles and drug development of METTL3 (methyltransferase-like 3) in anti-tumor therapy. Eur J Med Chem. 2022;15:114118.
211. Yankova EA-O, Blackaby W, Albertella M, Rak J, De Braekeleer E, Tsagkogeorga G, Pilka EA-O, Aspris D, Leggate D, Hendrick AA-O, Webster NA, Andrews B, Fosbeary R, Guest P, Irigoyen NA-O, Eleftheriou M, Gozdecka M, Dias JA-O, Bannister AA-O, Vick BA-O, Jeremias IA-O, Vassiliou GA-O, Rausch OA-O, Tzelepis KA-O, Kouzarides T. A.-O., Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia. Nature. 2021;593(7860):597–601.
212. Xiao H Zhao R Meng W Liao Y Effects and translatomics characteristics of a small-molecule inhibitor of METTL3 against non-small cell lung cancer J Pharm Anal 2023 13 6 625 39 10.1016/j.jpha.2023.04.009 37440912
Xiao H, Zhao R, Meng W, Liao Y. Effects and translatomics characteristics of a small-molecule inhibitor of METTL3 against non-small cell lung cancer. J Pharm Anal. 2023;13(6):625–39.37440912
213. Dolbois AA-O Bedi RK Bochenkova E Müller A Moroz-Omori EA-O Huang D Caflisch AA-O 1,4,9-Triazaspiro[5.5]undecan-2-one Derivatives as Potent and Selective METTL3 Inhibitors J Med Chem 2021 9 17 12738 60 10.1021/acs.jmedchem.1c00773
Dolbois AA-O, Bedi RK, Bochenkova E, Müller A, Moroz-Omori EA-O, Huang D, Caflisch AA-O. 1,4,9-Triazaspiro[5.5]undecan-2-one Derivatives as Potent and Selective METTL3 Inhibitors. J Med Chem. 2021;9(17):12738–60.
214. Moroz-Omori EA-O, Huang D, Kumar Bedi R, Cheriyamkunnel SJ, Bochenkova E, Dolbois A, Rzeczkowski MD, Li Y, Wiedmer L, Caflisch A. METTL3 Inhibitors for Epitranscriptomic Modulation of Cellular Processes. ChemMedChem. 2021;16(19):3035–3043.
215. Du Y Yuan Y Xu L Zhao F Wang W Xu Y Tian X Discovery of METTL3 Small Molecule Inhibitors by Virtual Screening of Natural Products Front Pharmacol 2022 Apr 2022 27 878135
Du Y, Yuan Y, Xu L, Zhao F, Wang W, Xu Y, Tian X. Discovery of METTL3 Small Molecule Inhibitors by Virtual Screening of Natural Products. Front Pharmacol 2022 Apr. 2022;27:878135.
